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Abstract 
 
DNA replication is a fundamental cellular process that ensures the accurate 
duplication and transmission of genetic information.  The replication machinery is 
frequently challenged by endogenous and exogenous sources of DNA lesions or 
barriers, which can interfere with replication fork progression.  If stalled replication forks 
are not properly stabilized and restarted, they can collapse, resulting in the generation 
of DNA double-strand breaks (DSBs).  Mis-repaired breaks lead to increased genome 
instability in the form of chromosomal deletions, amplifications, and aberrant 
rearrangements.  These detrimental alterations characterize many human diseases and 
can contribute to malignant transformation and the progression of cancer.  Therefore, 
the cell has evolved intricate mechanisms to promote the efficient resolution of 
replication stress. 
The repair of stalled or collapsed replication forks requires precise nucleolytic 
processing of DNA intermediate structures.  However, the molecular details of these 
processing events are not well defined.  We describe a critical role for the DNA 
nuclease, SNM1B, in the resolution of replication stress and uncover potential 
mechanisms for its regulation.  We found that SNM1B is dispensable for the detection of 
stalled forks, as it localizes independently to sites of stress after early-response 
proteins.  DNA fiber analyses and immunofluorescence assays also revealed that 
SNM1B is important for efficient replication restart and for preventing the accumulation 
of single-stranded DNA intermediates and DSBs at stalled forks.  Using a 
chromosomally integrated substrate that induces site-specific replication fork arrest in 
mammalian cells, we showed that SNM1B is required for the recombination-mediated 
repair of DSBs after fork collapse.  Together, these findings highlight the importance of
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SNM1B in accurately processing DNA intermediates and in preserving genomic integrity 
during DNA replication.  
DNA repair pathways are tightly controlled and coordinated within the cell cycle 
to safeguard genetic information.  The regulation of nucleases is especially important as 
inappropriate DNA resection can lead to fragile DNA structures or mis-repaired 
substrates.  Little is known about the regulation of the SNM1B nuclease; thus, we 
sought to identify the mechanisms underlying the control of its functions and stability 
within the cell cycle.  We found that SNM1B protein levels are stabilized during S-phase 
in response to agents that induce replication stress and that SNM1B is phosphorylated 
on its C-terminus in G2-phase and mitosis.  Investigations using non-phosphorylatable 
mutants demonstrated that SNM1B phosphorylation is dispensable for its localization to 
stalled forks, but may promote protein stability by preventing polyubiquitination during 
mitosis.  Overall, these studies define a novel role for SNM1B in resolving stalled 
replication forks and provide insight into the regulatory mechanisms necessary for the 
prevention of replication-associated DNA damage. 
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Chapter 1 
Introduction 
 
Eukaryotic DNA Replication 
 The faithful transmission of genetic information depends on accurate DNA 
replication and chromosome segregation.  These processes occur during the cell cycle, 
a carefully orchestrated series of events that allows for the proper duplication and 
division of genomic DNA into two daughter cells.  The prototypical cell cycle in 
eukaryotes is divided into four phases.  In the synthesis phase (S-phase), the nuclear 
DNA is replicated, which is then separated and equally distributed to the newly forming 
daughter cells in mitosis (M-phase).  S-phase and mitosis are separated by two gap 
phases, G1- and G2-phase, which prepare the cells for DNA replication and division, 
respectively 1.   
 The initiation of eukaryotic DNA replication occurs in a two-step process: origin 
licensing and origin firing.  Origin licensing occurs during late mitosis or G1-phase of the 
cell cycle, when the origin-recognition complex (ORC) binds to defined replication 
origins throughout the genome and recruits a set of licensing factors.  Together, these 
factors load the minichromosome maintenance (MCM) helicase around DNA at each 
origin to form the inactive pre-replication complex (pre-RC).  In S-phase, the pre-RC is 
converted into the active CMG helicase comprised of MCM, CDC45, and the tetrameric 
GINS complex, which together initiate bidirectional origin firing.  The leading-strand 
polymerase, Pol e, and the lagging-strand polymerases, Pol d and Pol a, associate with 
the CMG complex to concomitantly replicate DNA 2–4.  
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Sources of Replication Stress 
In order for successful completion of DNA synthesis, ongoing replication forks 
must advance in a timely and efficient manner.  When the progression of replication 
forks is slowed, blocked, or stalled, this results in what is referred to as replication 
stress.  Replication stress can be caused by a variety of endogenous and exogenous 
sources, and if not properly resolved, can lead to deleterious effects on genome stability 
(Figure 1.1) 5,6.  One of the most common types of replication stress is unrepaired DNA 
lesions, which can occur at a rate of up to 105 per day 7.  These spontaneous alterations  
result from dNTP misincorporation, DNA base modifications, or DNA deamination or 
depurination 8.  By-products of cellular metabolism, such as reactive aldehydes and 
reactive oxygen species (ROS), are endogenous sources of DNA lesions that block 
replication fork progression 9,10. 
Collisions between the replication fork and DNA-protein complexes are an 
additional barrier to the progression of DNA synthesis.  One DNA-protein complex that 
the fork may encounter is the transcription machinery.  Although DNA replication and 
transcription are coordinated processes that are spatially and temporally separated, 
there are circumstances in which the two machineries can converge 11–13.  The 
consequences of this collision include increases in topological stress and/or the 
formation of DNA-RNA structures called R-loops, which can result in DNA damage if left 
unresolved 12,13.  Additionally, replication forks stall if there is improper control of 
replication initiation or if resources required for this process are limited.  For example, 
excessive origin firing can result in depletion of the nucleotide pools while the firing of 
too few origins can lead to under-replication and loss of genomic information 14,15.  
Replication forks also encounter specific DNA sequences or genomic loci that 
are difficult to replicate.  Trinucleotide repeats and GC-rich DNA can form secondary 
structures, such as hairpins or G-quadruplexes, that can block or slow fork progression 
16,17.  Additionally, common fragile sites (CFSs) are regions within the genome that are 
sensitive to replication stress.  CFSs are found in all individuals and exhibit instability in 
the form of gaps and breaks in metaphase chromosomes after mild inhibition of DNA 
synthesis 18–21.  The mechanism of CFS instability is not fully understood, but there are 
several characteristics of CFSs that may make them sensitive to replicative damage.  
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CFSs are enriched within large genes that span hundreds of kilobases and require more 
than one cell cycle to transcribe.  Active transcription of these genes could therefore 
increase the probability of collisions between the replication fork and the transcription 
machinery 22–24.  CFSs also have the potential to form secondary DNA structures, are 
late replicating, and are located in regions that contain fewer origins, making them more 
susceptible to incomplete DNA replication 25–27.       
 Overexpression or activation of oncogenes is an additional source of replication 
stress.  Oncogenes, such as HRAS, C-MYC, and Cyclin E, can cause premature entry 
into S-phase and promote mis-regulated replication initiation and origin firing 28.  This 
leads to a decrease in nucleotide pools and an increase in replication-transcription 
collisions 28.  Although the precise mechanism of oncogene-induced replication stress is 
still being uncovered, it is clear that it can contribute to genome instability and 
tumorigenesis. 
 Exogenous sources of replication stress also exist and are frequently used in the 
laboratory to examine the effects of replication fork stalling.  The most common extrinsic 
sources are ultraviolet (UV) radiation and genotoxic chemical compounds that can 
generate a broad spectrum of replication-blocking DNA lesions 29.  Exposure to UV 
radiation induces the formation of pyrimidine dimers that uncouple leading- and lagging-
strand replication 30.  Chemical compounds can also cause bulky DNA lesions or DNA 
crosslinks, which occur when nucleotides are covalently linked within a single DNA 
strand (intrastrand crosslink) or between the two opposite strands of the DNA double-
helix (interstrand crosslink – ICL) 31.  These lesions are induced by the 
chemotherapeutic agents, cisplatin or mitomycin C (MMC).  ICLs act as a replication 
barrier because they prevent strand separation and must be properly unhooked, 
bypassed, and repaired before the replication fork can progress 32,33.  DNA lesions are 
also produced by the alkylating agent, methyl methanesulfonate (MMS), which blocks 
replication forks by attaching alkyl groups to DNA 34. 
 Other agents that induce replication stress do not damage the DNA directly, but 
instead interfere with replication-associated enzymes 29.  Hydroxyurea (HU) interferes 
with the ribonucleotide reductase (RNR), which consequently disrupts the metabolism of 
dNTPs.  This perturbs the incorporation of nucleotides into the replicating DNA and 
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halts synthesis 35,36.  Camptothecin (CPT) and etoposide (ETP) target topoisomerase I 
(TOPI) and topoisomerase II (TOPII), respectively, which act beyond the replication fork 
to relax supercoiled DNA.  Stabilization of these cleavage complexes by CPT and ETP 
results in collisions with the replication machinery 37,38.  Aphidicolin (Aph) induces 
replication stress by inhibiting the DNA polymerases a, d, and e.  This forces the 
uncoupling of the polymerase and helicase activities, resulting in long stretches of 
single-stranded DNA (ssDNA) that are vulnerable to breakage 39–41. 
Pathways for Resolving Replication Stress 
 Cells have evolved complex surveillance mechanisms to detect and respond to 
DNA damage and replication stress.  The DNA damage response (DDR) is coordinated 
by three major proteins of the phosphatidylinositol 3-kinase-related kinase (PIKK) family 
– ATM, ATR, and DNA-PKcs 42,43.  Ataxia telangiectasia-mutated (ATM) and DNA-
dependent protein kinase (DNA-PKcs) are primarily involved in DNA double-strand 
break (DSB) repair and signaling, whereas ATM- and Rad3-related (ATR) responds to a 
broader spectrum of DNA damage, specifically those associated with DNA replication 
44–46.  All three DDR kinases act by sensing the DNA damage through protein-protein 
interactions and by initiating a cellular signaling cascade of phosphorylation events to 
promote repair and activation of cell cycle checkpoints.  
 ATR is the key responder to genotoxic stress associated with stalled 
replication forks.  Although replication stress is triggered by a variety of sources, it 
usually results in the formation of long stretches of ssDNA 47.  This often occurs from 
helicase-polymerase uncoupling or from the nucleolytic processing events at stalled 
forks 48.  When ssDNA is generated, it is rapidly coated by the ssDNA-binding protein 
complex, replication protein A (RPA).  This constitutes the signal for recruiting ATR 
via its binding partner, ATRIP 49.  Another regulator of ATR is the RAD9-RAD1-HUS1 
(9-1-1) complex, which loads onto DNA at RPA-coated ssDNA-dsDNA junctions.  
DNA topoisomerase II binding protein 1 (TOPBP1) interacts with ATR-ATRIP and the 
RAD9 subunit of the 9-1-1 complex to fully activate ATR 50,51.  Once activated, ATR 
can initiate a signaling cascade by phosphorylating downstream targets, such as the 
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effector kinase CHK1 and members of the Fanconi anemia (FA) pathway or the 
FA/BRCA network.    
 The FA pathway is comprised of at least 21 known genes (FANCA-FANCV).  
Inactivation of any one of these genes causes Fanconi anemia, an inherited genome 
instability disorder characterized by bone marrow failure, developmental defects, and a 
predisposition to cancer 52.  The most well-defined function of the FA pathway is in the 
repair of ICLs, as FA patient cells are hypersensitive to agents that induce this type of 
lesion, but additional evidence has demonstrated roles for FA proteins in other repair 
processes and in the stabilization of stalled replication forks 53.  In response to 
replication stress, the ATR kinase activates the FA core complex (FANCA, B, C, E, F, 
G, L, M, T, FAAP100, MHF1, MHF2, FAAP20 and FAAP24), which then loads onto 
chromatin at sites of damage 54–56.  This complex monoubiquitinates the FANCD2-I 
heterodimer through its ubiquitin ligase subunit, FANCL, and the ubiquitin conjugating 
enzyme, UBE2T (FANCT) 57.  Monoubiquitinated FANCD2-I can localize to chromatin 
and recruit downstream factors of the FA/BRCA network, including BRCA2 (FANCD1), 
RAD51 (FANCR), FANCJ (BRIP1), FANCN (PALB2), and SLX4 (FANCP) 58–60.  These 
proteins have important functions in stabilizing stalled forks and in recombination-
mediated repair following fork collapse. 
 Unlike ICLs that illicit repair through the FA/BRCA network, some lesions can 
stall the replicating polymerases without physically blocking the unwinding helicase.  In 
the case of unrepaired lesions or base modifications on the leading-strand, the 
replisome can bypass these obstructions via DNA damage tolerance (DDT) 
mechanisms.  The replication machinery can reprime or reinitiate DNA synthesis 
downstream of the lesion, leaving behind a ssDNA gap.  This gap is filled in by 
specialized translesion synthesis (TLS) polymerases that replicate through the 
damaged template or by recombination-mediated repair involving template switching to 
the newly synthesized sister chromatid 61.  If left unrepaired, the ssDNA gap can be 
converted into a DSB and promote genome instability. 
Despite the diversity of replication fork impediments, ssDNA accumulation is a 
common feature of all stalled forks 47.  The ssDNA is often generated through 
polymerase-helicase uncoupling, but this uncoupling event is not feasible when physical 
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blocks, such as ICLs or DNA-protein complexes, block progression of the helicase.  
Therefore, the blocked replication forks must be processed in a way that generates 
stretches of ssDNA for proper signaling and repair.  One method of processing is 
through replication fork reversal, which is a global response to various types of 
genotoxic stress 47.  During fork reversal, the parental DNA strands reanneal and the 
complementary nascent leading- and lagging-strands anneal to form a four-way junction 
62–64.  This junction produces a fourth regressed arm at the fork and is often referred to 
as a “chicken foot” structure.  Several DNA translocases and helicases have been 
implicated in initiating fork regression, including FANCM, SMARCAL1, HLTF, FBH1, 
ZRANB3, BLM, and WRN 65–71.  Another required component for fork reversal is the 
recombinase RAD51, which promotes homologous pairing and strand exchange of 
ssDNA.  RAD51 has been proposed to either bind to the parental ssDNA to drive 
reversal or to the ssDNA of the regressed arm to capture the reversed fork 72.    
 After the replication fork is regressed, it must be processed or remodeled to allow 
for replication restart (Figure 1.2).  The RecQ family of helicases have been described 
to facilitate fork restart after reversal.  The RECQ1 helicase promotes branch migration 
of the reversed fork and is regulated by poly(ADP-ribose) polymerase 1 (PARP1), which 
suppresses the activity of RECQ1 until the replication stress is relieved 73.  RECQ1 
binding can also inhibit a second pathway of fork restart mediated by the Werner 
syndrome ATP-dependent helicase (WRN) and the DNA replication ATP-dependent 
helicase-nuclease (DNA2).  WRN and DNA2 can restart forks by unwinding and 
resecting the regressed arm with a 5’ to 3’ polarity 74.  The resulting 3’ overhang could 
recruit another motor protein to drive branch migration or it could activate 
recombination-mediated restart by invading donor sequences ahead of the reversed 
fork 75,76.  
 Additional nucleases have been implicated in processing stalled replication forks 
to promote restart, but the specific DNA structures that they act upon are not fully 
established 76.  The Fanconi-associated nuclease 1 (FAN1) and the C-terminal binding 
protein interacting protein (CtIP) both cooperate with FANCD2 to aid in fork recovery 
77,78.  Additionally, PARP1 has been shown to recruit the meiotic recombination 11 
(MRE11) nuclease to stalled forks to promote DNA resection for recombinational repair 
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and restart 79.  MRE11 has also been implicated in generating ssDNA gaps at stalled 
replication forks, which may enable RAD51 filament formation to facilitate fork reversal 
or template switching 80,81.  Exonuclease 1 (EXO1) has been described to perform a 
similar function in yeast, although the structure of the fork in this scenario is unknown 
and DNA degradation by EXO1 may counteract fork reversal 82. 
The nucleolytic processing of nascent DNA at stalled forks is an integral step for 
replication restart, but dysregulated nuclease activity can lead to uncontrolled 
degradation and genome instability.  Therefore, the cell has evolved mechanisms to 
monitor and protect the fork from excessive DNA end resection.  Members of the 
FA/BRCA network play key roles in stabilizing stalled forks and preventing extensive 
degradation by the nucleases EXO1 and MRE11 83–86.  Fork protection is dependent on 
the stabilization of RAD51 filaments, which is facilitated by BRCA1, BRCA2, and 
FANCD2 80,83,84.  
If stalled replication forks remain unstable and fail to restart, they may collapse 
and generate DNA DSBs.  These breaks can form by endonucleolytic cleavage of 
irresolvable fork structures or vulnerable ssDNA regions.  The endonuclease MUS81 
has been implicated in these cleavage events at reversed forks, and once generated, 
the DSBs are repaired via homologous recombination (HR) 87.  DNA end resection by 
the coordinated activities of MRE11, CtIP, EXO1, and DNA2 produces the 3’ overhangs 
necessary for initiating recombination 88–92.  These overhangs are coated by the ssDNA-
binding protein RPA, which is then displaced by the RAD51 recombinase.  The RAD51 
filaments coordinate homology search and strand invasion to initiate DNA synthesis 
using a homologous template 93.  The downstream factors of the FA/BRCA network, 
such as BRCA1 and BRCA2, aid in this process independently of their protective roles 
at stalled replication forks.     
Consequences of Unresolved Replication Stress 
 The DNA intermediates that form in response to replication stress play an 
integral role in the repair process, but if not properly resolved, they can result in 
pathological consequences.  Defects in the signaling events or mis-repair at stalled 
forks can lead to genome instability and disease.  For example, loss of the ATR kinase 
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or mutations in its binding partner ATRIP can cause Seckel syndrome, a disorder 
characterized by developmental delay and microcephaly 94–96.  Similarly, helicases that 
aid in fork remodeling and stabilization are also associated with disease.  The RecQ 
helicases, BLM and WRN, are mutated in patients with Bloom syndrome and Werner 
syndrome, respectively, which are both characterized by premature aging, growth 
retardation, and cancer predisposition 97.  A disease with clinically overlapping 
symptoms with Bloom and Werner syndrome is Fanconi anemia.  Inherited mutations in 
any one of the known FA genes can cause this heterogeneous autosomal recessive 
disorder, with the exception of the X-linked gene FANCB or the rare dominant negative 
mutations of RAD51 (FANCR).  Patients with FA display skeletal abnormalities, 
developmental delays, growth retardation, and bone marrow failure 59.  Interestingly, 
monoallelic inactivation of genes within the BRCA portion of the FA/BRCA network, 
including BRCA1 (FANCS), BRCA2 (FANCD1), FANCN, and FANCJ, can cause an 
increased predisposition to breast and ovarian cancer 98.  Additionally, somatic FA gene 
mutations have also been identified in sporadic cancers of individuals without FA 99.    
 Processes associated with genome maintenance, such as DNA replication and 
repair, bear an intrinsic risk of mutagenesis.  Errors during replication have the potential 
to induce deleterious copy number variants (CNVs), which are defined as deletions or 
duplications of genomic regions ranging from 50 base pairs to megabases in length 100.  
CNVs have been associated with genetic and neurodevelopmental disorders, including 
autism and schizophrenia, and they arise frequently in cancer 101,102.  A large proportion 
of pathogenic CNVs are nonrecurrent and contain breakpoint microhomologies, 
indicative of aberrant template switching at stalled replication forks.  In these models of 
CNV formation, stalled forks can utilize another active fork as a template to resume 
replication, or one-ended DSBs at collapsed forks can undergo template switching into 
regions of microhomology in an attempt to repair the break 103,104.  Intriguingly, CNV 
hotspots occur in the same genomic loci as CFSs, which as described previously, are 
regions prone to breakage from replication stress.  These loci associate with late-
replicating, large, active transcription units that can stall replication due to R-loop 
formation and/or collisions between the transcription and replication machinery.  The 
two most frequent CFSs, FRA3B and FRA16D, map within the large tumor suppressor 
 
9 
genes, FHIT and WWOX, respectively 105,106.  These genes were found to be sites of 
recurrent deletions in various cancers, and the loss of gene expression is associated 
with tumor progression and decreased survival 107–109.  Therefore, replication errors at 
CFSs can lead to genome instability and promote tumorigenesis.   
Cell Cycle Control of DNA Repair Processes 
 Genome maintenance and DNA repair processes are tightly linked to the cell 
cycle.  When a cell is exposed to genotoxic stress, the repair pathway choice often 
depends on the type of damage encountered and on the cell cycle phase 110,111.  The 
most prominent example of this modulation is in the periodic inhibition of DSB repair.  
The two main pathways of DSB repair include non-homologous end-joining (NHEJ) and 
HR.  NHEJ functions by directly ligating broken DNA ends together, whereas HR repairs 
DSBs through extensive end processing and DNA synthesis using a homologous 
template 88,112.  Because HR requires a homologous sequence, such as a duplicated 
sister chromatid, this pathway functions primarily during S- and G2-phase when 
replicated DNA is present.  Alternatively, DSBs that form during G1-phase are 
predominantly repaired by NHEJ.  This is due to the absence of sister chromatids and to 
the high compaction of DNA at this stage. 
 The regulation of DSB repair by the cell cycle is partially dictated by the extent of 
DNA end resection.  The cyclin-dependent serine/threonine kinases (CDKs), which 
partner with cyclins to drive cell cycle progression, also play a role in mediating end 
resection 113.  CDK activity levels rise during S- and G2-phase, leading to the 
phosphorylation and stimulation of CtIP, EXO1, and DNA2, which are all nucleases 
involved in the DNA processing events associated with HR 114–116.  Alternatively, p53-
binding protein 1 (53BP1) promotes NHEJ in G1-phase by blocking resection and 
opposing HR 117–119.  The interplay between these events is an important factor in 
determining DSB repair pathway choice in different phases of the cell cycle.    
 The primary goal of mitosis is the successful segregation of sister chromatids; 
however, unresolved DNA replication intermediates can result in linked chromatids that 
fail to separate during anaphase.  Therefore, components of the HR pathway remain 
active in early mitosis to process these intermediates.  CDK-dependent phosphorylation 
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promotes the formation of the MUS81-EME1-SLX1-SLX4 nuclease complex, which 
resolves the joint DNA structures 120.  Incomplete replication at loci such as CFSs also 
poses a problem for chromatid segregation, and the endonuclease MUS81-EME1 has 
been implicated in cleaving the branched structures at CFSs 121,122.  Studies have 
shown that MUS81-EME1 can also promote POLD3-dependent DNA replication at 
these loci in a process called mitotic DNA synthesis (MiDAS) 123.  MiDAS may help 
minimize chromosome mis-segregation through a microhomology-mediated repair 
mechanism independent of the canonical HR proteins, BRCA2 and RAD51 124.  If DNA 
is not properly processed at CFSs, the chromatids remain linked, forming anaphase or 
ultra-fine bridges (UFBs) 125.  Additional repair factors, such as BLM and FANCD2, 
localize to UFBs in an attempt to facilitate disjunction, and defects in this process can 
lead to micronucleation 126,127.   
 Most of the DNA damage that is repaired during mitosis is propagated from S- or 
G2-phase, but there is evidence that DSBs can occur in mitotic cells.  Mitotic cells 
sense the DSBs and initiate a signaling cascade, but they do not repair the breaks after 
late prophase or prevent the progression of cell division 128.  The early signaling events 
in the pathway are unaffected, but modifications of downstream effectors interrupt their 
canonical repair functions.  Specifically, phosphorylation of 53BP1 disrupts its 
accumulation on damaged chromatin, thereby preventing efficient NHEJ 129–132.  This 
disruption is particularly evident at mitotic telomeres, where NHEJ is blocked to allow for 
telomere uncapping and to prohibit end-to-end chromosome fusions 130.  Because the 
initial signaling cascade is intact, DSBs that occur in mitosis are “marked” for repair in 
the following G1-phase when the chromatin environment is more favorable 129.           
Regulation of DNA Repair  
The regulation of DNA repair throughout the cell cycle relies heavily on post-
translational modifications (PTMs).  PTMs are important for the complex DNA damage 
response because they allow for the rapid and precise control of protein function by 
altering protein activity, localization, and interactions.  The most common PTMs that 
regulate the DDR include phosphorylation, ubiquitination, SUMOylation, and 
PARylation.  
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Protein phosphorylation is a key event in most signaling cascades, especially 
during the DDR.  The protein kinases ATM, ATR, and DNA-PKcs are activated by 
autophosphorylation and they initiate the cellular responses to DNA damage by 
phosphorylating an extensive network of substrates 43.  One major role of these 
phosphorylation events is the activation of cell cycle checkpoints, which provide the 
cells with additional time to repair DNA damage or resolve replication stress before 
proceeding with cell division.  Phosphorylation can also modulate the functions of 
specific proteins that act in multiple pathways of repair.  For example, the DNA helicase 
BLM is phosphorylated by ATR to aid in replication fork recovery, whereas in mitosis, it 
is phosphorylated by MPS1 to facilitate checkpoints that ensure faithful chromosome 
segregation 133,134.   
Ubiquitination is another PTM that is important for maintaining genome integrity 
and regulating DNA repair.  Ubiquitin is a small peptide that is covalently attached to 
lysine residues, either as a single modification (monoubiquitination) or as a linked chain 
(polyubiquitination).  Polyubiquitination on defined lysines, specifically K48 or K29, 
targets proteins for degradation by the proteasome, whereas monoubiquitination or K63 
polyubiquitination can regulate DNA repair processes 135,136.  One major example of this 
type of modification is FANCD2 monoubiquitination, which is important for localization of 
FANCD2 to sites of replication stress 52.  Proliferating cell nuclear antigen (PCNA), 
which is an essential replication factor, is also ubiquitinated during cellular responses to 
DNA damage.  PCNA is mono- and polyubiquitinated to recruit DNA polymerases for 
translesion synthesis or to promote an alternative pathway of error-free lesion bypass, 
respectively 110,137.  Another mechanism for regulating DNA repair is through alterations 
in protein levels and stability.  K48 polyubiquitination can facilitate this process by 
targeting proteins for degradation by the proteasome.  For example, BLM is 
polyubiquitinated and degraded to modulate its levels throughout the cell cycle 138,139.  
The FA member, FANCM, is also polyubiquitinated in mitosis to ensure its removal from 
chromatin when it is no longer required for replication fork repair 140. 
Similar to ubiquitin, small ubiquitin-like modifier (SUMO) is covalently attached to 
other proteins to modify their cellular functions.  SUMOylation of PCNA on multiple sites 
is predicted to help prevent replication fork collapse and DSB formation 141.  SUMO 
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modification of BLM is also required at stalled forks to efficiently recruit BRCA2 and 
prevent excessive ssDNA accumulation 142.  Poly(ADP-ribosyl)ation (PARylation) is a 
PTM catalyzed by the poly(ADP-ribose) polymerase (PARP) family of enzymes.  It is 
comprised of both linear and branched polymers of poly(ADP-ribose) (PAR) on multiple 
amino acid residues.  PARylation plays a pivotal role in DNA damage repair, as 
demonstrated by the hypersensitivity of Parp1 knockout mice to various genotoxic 
agents 143.  PARP1 localizes to single-strand breaks (SSBs) and DSBs to facilitate the 
recruitment of DDR proteins, such as MRE11 and ATM, potentially through PARylation 
of other targets 144–146.    
Several DNA repair proteins have roles in multiple pathways or respond to 
diverse forms of DNA damage.  Therefore, PTMs provide a practical mechanism for 
fine-tuning protein functions within different pathways or throughout various stages of 
the cell cycle.  DNA nucleases have been implicated in the resolution and repair of 
numerous types of DNA damage and studies have demonstrated that their nucleolytic 
activities must be tightly controlled to prevent genome instability.  However, the precise 
mechanisms of their regulation are not well characterized.  One exonuclease that has 
been described to function in the resolution of replication stress and in the DDR is 
SNM1B.  This thesis is focused on elucidating the role of SNM1B in replication repair 
and on its regulation by PTMs throughout cell cycle.       
Identification of SNM1B 
The SNM1 (sensitivity to nitrogen mustard) gene family was first discovered in 
genetic screens in Saccharomyces cerevisiae for hypersensitivity to the ICL-inducing 
agents, nitrogen mustard and psoralen 147,148.  These screens identified the founding 
member of this family, SNM1 or PSO2 (sensitivity to psoralen), which has five putative 
homologs in mammals: SNM1A, SNM1B/Apollo, SNM1C/Artemis, CPSF73, and ELAC2 
149–153.  These proteins are characterized by a common metallo-β-lactamase (MBL) fold 
and an appended βCASP domain (β-CPSF-Artemis-SNM1/PSO2), which together 
provide nucleolytic function.  The canonical MBL fold contains five conserved sequence 
motifs that participate in metal ion coordination and hydrolysis of various substrates 154.  
Motif 2 contains the highly conserved HxHxDH sequence, which serves as the active 
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site for this class of enzymes 154,155.  Mutation of the aspartic acid (D) in motif 2 has 
been shown to disrupt the nuclease activity of both Artemis and SNM1B 156–158.  The 
βCASP domain is unique to the SNM1 members of the MBL superfamily and 
contributes to their nucleic acid binding capabilities.  An analysis of the amino acid 
sequences revealed a set of three conserved residues within the βCASP domain, which 
are all located at the end of predicted β-strands 154.  A valine within the last motif is 
characteristic of DNA processing enzymes, such as SNM1A, SNM1B, and Artemis, 
whereas a histidine is characteristic of the RNA processing enzymes, CPSF73 and 
ELAC2 154.  Therefore, the residue within this motif appears to be responsible for 
distinguishing between RNA and DNA specificity within the metallo-β-lactamase/βCASP 
family, although the importance of the histidine residue in nucleolytic activity has been 
disputed 159. 
The metallo-β-lactamase/βCASP domain is the region of highest conservation 
between SNM1A, SNM1B, and SNM1C/Artemis, with the remaining sequences being 
distinct to each protein (Figure 1.3).  Although the members of this family share a similar 
catalytic domain, the specificity of their nucleolytic activities differ.  SNM1A and SNM1B 
both possess 5′ to 3’ exonuclease activity, whereas Artemis functions mainly as a 
structure-specific endonuclease 156,160,161.  Both SNM1A and SNM1B can digest short 
double-stranded and single-stranded DNA substrates with similar catalytic efficiency, 
but SNM1A becomes more processive on higher molecular weight DNA 
oligonucleotides 159.  They can both also digest past an ICL, but with SNM1A 
functioning at a higher capacity through this type of lesion 159,162.  The nucleolytic activity 
of SNM1A supports the findings that it functions in ICL repair, and recent evidence 
suggests that it may also possess endonuclease activity to aid in this process 151,163.  
Artemis is a structure-specific nuclease that can act on 5’ and 3’ overhangs and on DNA 
hairpin substrates during V(D)J recombination and NHEJ 156,164,165.  Artemis has 5’ to 3’ 
exonuclease activity on its own, but its endonuclease activity is dependent on an 
interaction with DNA-PKcs.  It has been proposed that autophosphorylation of DNA-
PKcs activates Artemis through phosphorylation of its inhibitory C-terminus, thereby 
promoting the dissociation of this region from the N-terminal catalytic domain 164–167.  
Finally, SNM1B and its 5’ to 3’ exonuclease activity have known roles in ICL repair, the 
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DNA damage response, and telomere maintenance, which will be discussed in the next 
few sections. 
Roles of SNM1B in the Response to Stalled Replication Forks 
Studies characterizing the role of SNM1B in DNA repair revealed that SNM1B-
deficient cells are sensitive to agents that induce ICLs, such as MMC or cisplatin, but 
not to UV 168–172.  Additionally, there is conflicting evidence on whether SNM1B-depleted 
cells are sensitive to IR 168–170,172.  These experiments were all done using different cell 
types, both human and chicken, so these discrepancies may be attributed to differences 
in species or cell line tested.  SNM1B-deficient cells also display an increase in 
chromosomal gaps, breaks, and radial structures after exposure to ICL-inducing agents, 
further highlighting a role for SNM1B in the repair of ICLs 168,170,171. 
Because SNM1B is involved in the cellular response to ICLs, its link to the FA 
pathway was investigated.  SNM1B is not required for the monoubiquitination of 
FANCD2 after MMC treatment, but is important for the efficient localization of FANCD2, 
BRCA1, and RAD51 to sites of ICL damage 171.  SNM1B was also shown to function 
epistatically with FANCD2 and FANCP/SLX4 in the response to ICL-induced replication 
stress and to suppress chromosomal aberrations 171,172.  The FA pathway not only 
responds to ICL damage, but is also essential for stabilizing and repairing stalled or 
collapsed replication forks.  SNM1B functions with the FA/BRCA network in the cellular 
response to stalled forks induced by the polymerase inhibitor, aphidicolin.  SNM1B-
deficient cells are hypersensitive to aphidicolin treatment and display a decrease in 
FANCD2 and BRCA1 localization to sites of replication stress 173.  Additionally, SNM1B 
depletion results in elevated levels of spontaneous and aphidicolin-induced 
chromosomal gaps and breaks, including breaks at common fragile sites 173.  Together, 
these data reveal an important function of SNM1B in the response to replication stress. 
Roles of SNM1B in Cell Cycle Checkpoints 
 The ATM and ATR protein kinases play central roles in initiating the signaling 
events of cell cycle checkpoints during S-phase.  Several studies have investigated the 
role of SNM1B in these signaling events after DNA damage or replication stress.  In 
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response to ICL-inducing agents, SNM1B depletion results in no change in ATR-
signaling events, but a decrease in ATM-mediated signaling 170.  Localization and 
phosphorylation of ATR substrates was also unaffected by SNM1B knockdown in cells 
treated with the DNA polymerase inhibitor, aphidicolin 173.  This suggests that SNM1B is 
not involved in the early ATR-signaling events in response to aphidicolin or ICL-induced 
damage.  However, the decrease in ATM-mediated signaling during ICL repair could be 
due to DSB formation that occurs from processing this type of lesion.  The ATM-
signaling events in SNM1B-deficient cells were also examined after IR treatment 168,170.  
These studies found conflicting results, which could be attributed to differences in the IR 
doses and timepoints examined.   
In addition to checkpoint signaling during S-phase, the role of SNM1B has also 
been examined in mitotic checkpoints.  SNM1B was shown to function in an early 
prophase checkpoint, which prevents DNA condensation and nuclear envelope 
breakdown when conditions are unfavorable for cell division 174.  Similar findings have 
also been reported for the MBL/βCASP family member, SNM1A 175.  The precise role of 
SNM1B in this prophase checkpoint is still unknown, but it suggests that SNM1B may 
promote successful cell cycle progression.    
Roles of SNM1B in Telomere Maintenance 
 Telomeres are the structures at the end of linear chromosomes, which consist of 
a G-rich repeat DNA sequence, the shelterin complex, and shelterin accessory factors 
176.  The shelterin complex binds to telomeric DNA to prevent the recognition of these 
ends as DSBs and to protect them from aberrant repair 177,178.  The shelterin complex 
associates with several accessory factors, which are distinguished from the core 
shelterin components by their lower abundance at telomeres or their transient 
association with the complex 177.  In mass spectrometry experiments, SNM1B was 
identified as a shelterin accessory factor that associates with the shelterin proteins, 
RAP1 and telomere repeat binding factor 2 (TRF2) 179.  Multiple groups have described 
the interaction between SNM1B and TRF2 using co-immunoprecipitation, yeast two-
hybrid screens, GST pulldown assays, co-immunofluorescence, and even isothermal 
titration calorimetry 161,179–182.  The last 37 amino acids (496-532) of SNM1B are 
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necessary and sufficient for binding to the TRF homology (TRFH) domain of TRF2, and 
this association is important for SNM1B localization to the telomere 161,179,180. 
 In addition to being capped by the shelterin complex, telomeres also form T-
loops as a mechanism to protect against DSB recognition.  T-loops are generated by 3’ 
overhangs that insert back into the double-stranded portion of the telomeric tract.  The 
5’ to 3’ exonuclease activity of SNM1B has been implicated in initiating the formation of 
the 3’ overhangs at leading-strand telomeres, and this resection is limited by the 
shelterin component, POT1b (Figure 1.4) 157,183,184.  SNM1B-depleted cells exhibit 
increased telomere dysfunction-induced foci (TIFs) and telomere fusions, indicative of 
unprotected chromosome ends 161,179.  Additionally, some telomeres in SNM1B-deficient 
cells showed two telomeric signals at single-chromatid ends, which suggests abnormal 
telomere structures 179.  Together, these data reveal an important role for SNM1B in 
DNA end resection at the telomere to protect it from aberrant DNA repair.  Studies have 
suggested that the generation of 3’ overhangs at chromosome ends reflects a role of 
SNM1B in telomere replication.  To separate functions of SNM1B in overhang 
maintenance and telomere replication, the cellular response to an internal telomeric 
sequence was examined.  SNM1B nuclease activity suppresses the DNA damage 
response at these internal telomeric sequences and functions in a complementary 
pathway with TOPIIa to relieve topological stress during telomere replication 158.  These 
findings provide evidence for a role of SNM1B in protecting telomeres from DSB repair 
and replicative damage.   
SNM1B Protein Interactions 
 Although TRF2 is the most well studied binding partner of SNM1B, several other 
proteins have been shown to interact with SNM1B in various contexts (Figure 1.5).  Co-
immunoprecipitation studies revealed that SNM1B directly interacts with MUS81 and 
with members of the MRN complex, specifically MRE11 and RAD50 170.  In the same 
report, SNM1B was also shown to interact indirectly with the FA protein, FANCD2, and 
all interactions were mapped to the N-terminal metallo-β-lactamase/βCASP domain of 
SNM1B 170.  Each of these described binding partners of SNM1B have known roles in 
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the DNA damage response, but the functional importance of these interactions has yet 
to be determined. 
 SNM1B has been previously described to function within the FA pathway, and 
this is further supported by the finding that SNM1B interacts with FANCP/SLX4 172.  This 
interaction was originally mapped to the N-terminal domain of SNM1B, but a recent 
review suggests that SLX4 instead binds to at least two unreported regions of SNM1B 
172,185.  SLX4 and SNM1B function epistatically in the response to MMC-induced ICL 
damage, and knockdown of SLX4 results in a decrease in SNM1B foci formation 172.  
These data provide additional evidence for a functional role of SNM1B in the FA 
pathway and in the repair of ICLs. 
 Because SNM1B has known roles in the response to replication stress, it is not 
surprising that it was found to associate with the replication protein, PSF2 (also known 
as GINS2) 186.  PSF2 is a member of the GINS complex, which functions in the initiation 
and elongation steps of DNA replication.  The interaction between SNM1B and PSF2 
was identified through a yeast two-hybrid screen and validated via co-
immunoprecipitation 186.  PSF2 binding was mapped to two regions within SNM1B, one 
of which encompasses the same site for TRF2 binding.  This study concluded that this 
C-terminal region of SNM1B competes with TRF2 binding and is required for chromatin 
association through an interaction with PSF2.  Alternatively, the more N-terminal binding 
site within SNM1B promotes the formation of a protein complex involving MUS81 and 
PSF2, but the functional importance of this complex remains unknown 186.  Interestingly, 
PSF2 has also been reported to interact with the FA core complex protein, FANCF, and 
knockdown of PSF2 results in sensitivity to ICLs and a reduction in FA core complex 
association with chromatin 187.  These data suggest that PSF2 may have a role in 
loading or stabilizing the FA core complex, and potentially SNM1B, onto chromatin 
during replication or in response to replication stress.  
 In another yeast two-hybrid screen, SNM1B was shown to interact with the 
spindle-associated protein, astrin, through its metallo-b-lactamase domain.  It was 
suggested that this interaction is important for proper activation of the prophase 
checkpoint during mitosis 174.  Mass spectrometry analyses have revealed additional 
binding partners of SNM1B, including heat shock proteins HSC70, HSP72, and HSP60, 
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and the microtubule component, b-tubulin 188.  HSP72 was shown to be required for 
proper SNM1B foci formation, but additional studies are necessary to elucidate the 
functional importance of these protein interactions with SNM1B.     
SNM1B and Disease 
A transcript variant of hSNM1B was identified in a patient with Hoyeraal-
Hreidarsson (HH) syndrome, a severe form of dyskeratosis congenita 189.  This patient 
presented with symptoms characteristic of HH syndrome, such as microcephaly, growth 
retardation, cerebellar hypoplasia, and aplastic anemia 189.  Analyses of primary 
fibroblasts derived from this patient revealed an intraexonic splice variant of SNM1B, 
which results in a frameshift and premature stop codon in the C-terminal end of the 
protein.  This leads to a loss of the last 116 amino acids, which includes the TRF2 
binding domain 189.  The primary fibroblasts displayed a growth defect, increased TIFs, 
and increased telomere fusions, but no abnormal telomere shortening compared to 
fibroblasts from healthy controls 189.  However, when cellular senescence is overcome 
by SV40 large T antigen transformation, expression of the SNM1B variant compromises 
the completion of lagging-strand replication and results in telomere shortening over 
time.  Ectopic expression of the variant in wildtype cells recapitulates the phenotypes 
observed in primary patient cells of HH syndrome, suggesting a dominant negative role 
of the SNM1B splice variant 189.  In contrast to defects observed at telomeres, cells 
expressing the SNM1B splice variant did not show sensitivity to MMC or IR 189.  
Together, these observations highlight a critical role for SNM1B at telomeres and 
suggest a separation of function of SNM1B in the DNA damage response and telomere 
maintenance.  
Although only one patient harboring a variant of SNM1B has been studied in 
depth, additional patients with symptoms of HH syndrome have been identified with 
SNM1B variants 190.  Several of these clinical variants have unknown significance, 
therefore their association with dyskeratosis congenita requires further investigation.  
Single nucleotide polymorphisms (SNPs) in SNM1B have also been evaluated in 
targeted or genome-wide cancer studies 191–195.  In an examination of DNA repair 
genes, SNM1B variants showed a suggested association with cutaneous malignant 
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melanoma 191.  Other SNPs in SNM1B have been associated with breast cancer, with 
one specific variant (rs11552449) showing differential splicing of exon 2 and decreased 
expression levels 193–195.  Cells that were heterozygous for this variant expressed higher 
levels of SNM1B containing exon 2 and were significantly more sensitive to MMC or IR 
compared to homozygous wildtype controls and showed no alterations in telomere 
length 196. Interestingly, when SNM1B was depleted in the breast cancer cell line, SK-
BR3, cell proliferation was increased compared to controls, which differs from the 
phenotype observed in other cancer cells 195.  This suggests that differential expression 
of SNM1B may contribute to the defects associated with cancer and may result in 
varying phenotypes in different cell lines. 
To date, no SNM1B null alleles have been identified in humans.  However, 
studies in mice have provided insight into the role of Snm1B during development.  To 
study the role of Snm1B in vivo, Snm1B knockout mice were generated by deletion of 
exon 4 157,197.  Deletion of this exon in Snm1B eliminates over 66% of the coding region, 
which includes the TRF2 binding site.  Snm1B homozygous null mice exhibit perinatal 
lethality with embryos displaying developmental delays and hypocellularity in multiple 
organ systems 197.  Snm1B-/- primary mouse embryonic fibroblasts (MEFs) generated 
from these mice showed a proliferation defect and increased apoptosis compared to 
wildtype controls 197.  This defect was attributed to high levels of telomere fusions, which 
could be rescued by deletion of the NHEJ factor Ku70 157,197.  Another mouse model of 
Snm1B, generated by deleting exons 2 and 3, also showed leading-end telomere 
fusions and a reduction in the telomeric overhang signal 183.  Together, these findings 
suggest an important role for SNM1B in embryonic development and protection of 
telomere ends from NHEJ repair.  It also indicates that SNM1B might be essential for 
survival in humans as well as in mice. 
Thesis Summary 
In this dissertation, I expand on the current knowledge of the functions of SNM1B 
in the resolution of stalled replication forks and provide insight into the mechanisms of 
its regulation.  In Chapter 2, I discuss our findings on the role of SNM1B in the response 
to replication stress.  We demonstrate that SNM1B is required for preventing the 
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accumulation of ssDNA intermediates and DSBs at stalled forks, thereby promoting fork 
stability and restart.  We also show that SNM1B facilitates the recombination-mediated 
repair of replication-associated damage.  In Chapter 3, I examine the regulation and 
post-translational modifications of SNM1B throughout the cell cycle.  I characterize a 
novel SNM1B phosphorylation event that occurs during G2-phase and mitosis to 
promote protein stability.  In Chapter 4, I discuss the implications of my findings and 
propose additional hypotheses relating to SNM1B and its role in DNA repair processes.  
Together, these studies define new functions for SNM1B in resolving stalled replication 
forks and provide a foundation for future explorations on the regulation of pathways that 
prevent genomic damage.     
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Figure 1.1 Sources of DNA replication stress 
Schematic highlighting the various obstacles or barriers that cause replication fork 
stalling.  Adapted from Zeman and Cimprich, 2014 5.     
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Figure 1.2 Resolution of stalled or collapsed replication forks 
Replication fork stalling leads to the accumulation of ssDNA (A).  The fork can become 
stabilized by the formation of a “chicken foot” structure, which entails reannealing of the 
parental DNA strands through a process called fork regression (B).  The nascent arm of 
the regressed fork can be resected by nucleases (C) or undergo template switching and 
branch migration (D) to promote fork restart.  Prolonged arrest results in fork collapse 
and the generation of DSBs (E).  The DNA ends at DSBs are resected (F) to initiate 
homologous recombination (G) and fork restart.  The purple arrow illustrates the 
direction of fork movement and the images with green proteins represent DNA 
structures on which DNA nucleases can act to facilitate repair. Adapted from Petermann 
and Helleday, 2010 198. 
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Figure 1.3 Protein domain alignment of the SNM1 family  
Alignment of the yeast Pso2 and mammalian SNM1 family of proteins depicting the 
conserved metallo-β-lactamase (MBL) and βCASP domains in light and dark grey, 
respectively.  The regions that are distinct to each protein are in white.  The canonical 
MBL motifs 1-4 are shown in blue and the βCASP motifs A-C are shaded green.  
Adapted from Sengerova et al., 2012 159.    
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Figure 1.4 SNM1B resects DNA ends at telomeres 
(A) Replication results in blunt ends at the leading-strand telomere and a short 
overhang bound by POT1 at the lagging-strand telomere. (B) TRF2 recruits SNM1B to 
the leading-strand telomere, and SNM1B resects the 5’ end to generate an overhang for 
subsequent processing and T-loop formation. (C) POT1 association with the single-
strand overhangs inhibits further resection by SNM1B.  Adapted from Arnoult and 
Karlseder, 2016 199. 
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Figure 1.5 Binding partners of SNM1B 
Schematic illustrating the functional domains and mapped protein interactions of 
SNM1B.  Unmapped binding partners of SNM1B are not depicted in this figure. 
MBL, metallo-β-lactamase; βCASP, β-CPSF-Artemis-SNM1/PSO2. Adapted from 
Schmiester et al., 2017 185.   
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Chapter 2 
SNM1B is Required for the Repair of Collapsed Replication Forks 
 
Abstract 
 The efficient resolution of stalled replication forks ensures proper duplication of 
the genome.  Defects in this repair process can result in under-replicated DNA and 
chromosomal aberrations.  The DNA nuclease, SNM1B, has been previously described 
to function in the repair of stalled and blocked forks to prevent genomic instability.  
Herein, we expand on the current knowledge of the roles of SNM1B during DNA 
replication.  We demonstrate that SNM1B becomes stabilized in response to agents that 
induce fork stalling and localizes independently to sites of replication stress after early-
response proteins.  SNM1B facilitates the stabilization and restart of stalled replication 
forks by preventing the accumulation of single-stranded DNA intermediates and double-
strand breaks (DSBs).  Using a chromosomally integrated substrate that models site-
specific replication fork arrest by the E. coli Tus/Ter termination complex, we show that 
SNM1B is required for the recombination-mediated repair of collapsed forks.  Overall, 
our findings reveal critical functions for SNM1B in accurately processing DNA 
intermediates during replication stress and in promoting recombinational repair of DSBs 
that result from prolonged fork arrest. 
 
Jordann Smak designed and performed the experiments shown in Figures 2.1; 2.2C; 
2.5; 2.S1; 2.S2; 2.S3 
Ishita Das designed and performed the experiments shown in Figures 2.2A,B; 2.3; 2.4
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Introduction 
The faithful replication of chromosomes is essential for the maintenance of 
genome stability.  However, the progressing DNA replication fork can often encounter 
impediments, such as unrepaired lesions, secondary DNA structures, or protein-DNA 
complexes, causing it to stall 1.  If these stalled forks are not properly stabilized or 
restarted, they can collapse and form DNA double-strand breaks (DSBs), which are 
then repaired through homologous recombination (HR).  Defects in this process can 
result in detrimental chromosomal breaks, deletions, or aberrant rearrangements 
associated with human disease and cancer 2–4. 
 The resolution of stalled replication forks requires the accurate processing of 
DNA intermediate structures, which is achieved through the coordinated actions of DNA 
nucleases 5,6.  When a replication fork stalls, it can undergo regression or reversal to 
generate a “chicken foot” structure.  This involves reannealing of the parental DNA 
strands and annealing of the complementary nascent leading- and lagging-strands 7–9.  
One proposed mechanism to resolve this structure and mediate fork restart is through 
nucleolytic degradation of the annealed nascent DNA.  MRE11, a member of the 
MRE11/RAD50/NBS1 (MRN) complex, is both an endonuclease and 3’ to 5’ 
exonuclease that has been implicated in this nucleolytic digestion at regressed forks 
10,11.  DNA2, EXO1, and FAN1 are all 5’ to 3’ exonucleases that have also been 
described to aid in this process 12–15.  Although nucleolytic resection at regressed forks 
can mediate fork restart, this process must be tightly regulated to prevent hyper-
degradation and deleterious effects 10,11,16,17. 
 If a stalled replication fork cannot be effectively restarted, it can collapse and 
generate DSBs. The endonuclease, MUS81, has been implicated in the formation of the 
DSB intermediate, which is then repaired via HR using the homologous sequence as a 
template 18,19.  Additional nucleases participate in the HR repair process by resecting 
the broken DNA ends to allow for strand invasion and subsequent DNA synthesis.  The 
initial limited 5’ DNA end resection is catalyzed by the nucleases, MRE11 and CtIP, 
whereas the processive long-range resection is attributed to the nuclease activities of 
EXO1 or DNA2, the latter in conjunction with the DNA helicases BLM or WRN 20–25.  
Once HR-mediated repair is complete, the replication fork can resume progression.  But 
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if the DSBs persist, the fork remains unrepaired, potentially resulting in detrimental 
chromosomal aberrations.  This highlights the importance of nucleases in processing 
DNA intermediate structures, but the precise coordination between these enzymes 
during the resolution of stalled replication forks is not well defined.      
 The SNM1B DNA nuclease also functions during the resolution of stalled 
replication forks.  SNM1B possesses 5’ to 3’ exonuclease activity and has known roles 
in processing DNA intermediates during interstrand crosslink (ICL) repair 26,27.  It is also 
implicated in DNA end resection at leading-strand telomeres to produce the 3’ 
overhangs for T-loop formation 28–30.  We previously found that SNM1B depletion results 
in hypersensitivity to the DNA polymerase inhibitor, aphidicolin (Aph). These SNM1B-
deficient cells display elevated levels of spontaneous and aphidicolin-induced 
chromosomal gaps and breaks, including breaks at common fragile sites (CFSs) 31.  
CFSs are particularly susceptible to breakage, as they reside in large, actively 
transcribed genes that are difficult to replicate 32.  Collisions between the replication and 
transcription machinery can contribute to the instability of these loci during DNA 
replication.  Additionally, we have previously shown that SNM1B localizes to sites of 
replication stress and is required for efficient recruitment of key DNA repair proteins, 
including FANCD2 and BRCA1, to stalled forks 27,31.  Studies have revealed that 
SNM1B physically interacts with FANCD2 and the nuclease, MRE11, which both 
function in HR 33.  However, the mechanisms underlying the regulation of SNM1B in 
DNA repair processes and the importance of its nucleolytic functions at stalled forks is 
not well understood.  In this study, we demonstrate that SNM1B is required for the 
efficient restart of stalled replication forks and that it is involved in the late-stage 
processing events of HR-mediated repair of DSBs upon fork collapse. 
Results 
SNM1B accumulates in S-phase cells synchronized by a double thymidine block 
 DNA repair processes are highly complex and need to be tightly controlled to 
prevent genome instability.  Some DNA repair proteins have multiple roles within 
different pathways of repair, and therefore need to be precisely regulated to perform the 
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appropriate functions.  One form of regulation is through changes in protein expression 
or stability.  For example, the DNA helicase, BLM, has been shown to be regulated by 
the cell cycle, with protein levels increasing in S- and G2-phases and decreasing in G1-
phase 34.  It is also stabilized in cells after exposure to agents that induce replication 
stress 34.  The DNA endonuclease, CtIP, is also regulated in a similar cell cycle-specific 
manner 35.  Therefore, this form of protein regulation could ensure that BLM, CtIP, and 
potentially other DNA repair proteins are only present and active during the phases in 
which they are required to function.   
Since SNM1B can process DNA intermediates that arise during DNA replication 
in S-phase, we hypothesized that SNM1B may be cell cycle regulated, similar to BLM 
and CtIP.  Because levels of endogenous SNM1B expression are too low to detect via 
Western blot, we generated HCT116 cell lines stably expressing an siRNA-resistant, 
V5-tagged SNM1B cDNA or an empty vector (EV) as a control (Figure 2.S1).  Cells 
expressing wildtype (WT) SNM1B were synchronized in early S-phase by a double 
thymidine block and released into fresh media for 0, 2, 4, or 6 hours.  Cells were 
harvested at each timepoint and SNM1B protein levels were assessed by 
immunoblotting.  At the time of release, when 45% of cells were in S-phase, SNM1B 
protein levels were approximately 2-fold higher than in the asynchronous population.  
After 6 hours, the levels of SNM1B decreased by ~25%, when only 17% of cells 
remained in S-phase (Figure 2.1A).  These results suggest that SNM1B is stabilized in 
S-phase and that protein levels are reduced as cells progress into G2-phase.   
SNM1B protein levels are not altered throughout the cell cycle in unperturbed cells 
The double thymidine block is a useful tool for cell synchronization, however, a 
caveat of this method is that it can induce replication stress through an imbalance of 
dNTP pools 37–40.  Thus, one potential explanation for the changes in protein levels 
observed in Figure 2.1A is that SNM1B may be stabilized in response to replication 
stress induced by the double thymidine block.  The levels of SNM1B are then reduced 
as cells recover from the stress.  To address this possibility, we examined SNM1B 
protein levels in unperturbed cells to see if SNM1B is regulated by the cell cycle.  
HCT116 cells stably expressing V5-tagged SNM1B were sorted based on their DNA 
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content using Hoechst staining and flow cytometry.  Cyclin A and B1 protein levels were 
used as controls to assess proper cell sorting.  SNM1B protein levels were similar 
across G1-, S-, and G2/M-phases (Figure 2.1B).  These data reveal that the SNM1B 
protein is not regulated by the cell cycle and that the increase in SNM1B levels after the 
double thymidine block is most likely due to stabilization in response to replication 
stress. 
SNM1B localizes to stalled forks after the recruitment of DNA repair proteins that 
function during early repair events 
 The finding that SNM1B is stabilized in S-phase supports the existing data that 
SNM1B is involved in the response to stalled replication forks 36.  SNM1B can localize to 
sites of replication stress and is highly associated with chromatin after treatment with 
the DNA polymerase inhibitor, aphidicolin (Figure 2.S2) 31.  However, the order of 
events that occur at these sites or the interplay between the proteins involved is not fully 
understood.   
SNM1B has been previously shown to be dispensable for the early ATR-
dependent signaling events in response to aphidicolin-induced stalled forks 31.  It is also 
not required for the proper localization of RPA and MRE11, which are DNA repair 
proteins that are involved in the initial response to replication stress.  However, there is 
evidence that SNM1B is necessary for the efficient localization of the downstream 
factors, FANCD2 and BRCA1, which are both important for recombination events during 
fork repair 31.  To gain a better understanding of the involvement of SNM1B in early or 
late repair events, the timing of SNM1B foci formation relative to other DNA repair 
proteins was analyzed.  HCT116 cells stably expressing V5-tagged SNM1B were 
treated with aphidicolin over a timecourse of 1 to 24 hours, and foci formation of RPA, 
MRE11, FANCD2, and SNM1B was assessed.  Approximately 40% of cells formed RPA 
and MRE11 foci after 1 hour of aphidicolin treatment, and this level persisted throughout 
the timecourse.  In comparison, only ~15% of cells formed SNM1B foci after 1 hour, and 
there was a slower accumulation of foci-positive cells over time.  Cells did not form 
FANCD2 foci until approximately 6 hours after aphidicolin treatment, and both SNM1B 
and FANCD2 foci-positive cells reached a maximum of ~35% after 24 hours (Figure 
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2.2A,B).  These data provide evidence that SNM1B localizes to stalled forks after the 
early-response proteins, RPA and MRE11, but before FANCD2, which functions 
downstream within the pathway.   
SNM1B recruitment to stalled forks is independent of MRE11 exonuclease activity 
Previous studies have reported that the nuclease activity of MRE11 promotes 
recruitment of BRCA1, FANCD2, and CtIP to aphidicolin-induced stalled forks 41.  
SNM1B is also involved in the localization of BRCA1 and FANCD2 and has been shown 
to physically interact with MRE11 31,33.  Since we observed that SNM1B forms foci after 
MRE11, we asked whether MRE11 nuclease activity is also required for recruitment of 
SNM1B to chromatin after aphidicolin treatment.  HCT116 cells stably expressing V5-
tagged SNM1B were pre-treated with the MRE11 exonuclease inhibitor, mirin, and then 
exposed to aphidicolin for 6 or 24 hours.  Cellular fractionations were performed to 
assess the levels of FANCD2, CtIP, and SNM1B in the chromatin fractions.  After both 6 
and 24 hours of aphidicolin exposure, the levels of CtIP and monoubiquitinated 
FANCD2 were reduced in the mirin-treated samples compared to the DMSO-treated 
controls.  In contrast, no change in SNM1B chromatin association was observed after 
mirin treatment (Figures 2.2C; 2.S3).  These findings indicate that MRE11 exonuclease 
activity is dispensable for SNM1B localization to stalled replication forks, but is required 
for proper recruitment of FANCD2 and CtIP, as previously described 41.   
 
SNM1B suppresses the accumulation of ssDNA at spontaneous and aphidicolin-
induced stalled forks 
 
 Although RPA localizes to stalled replication forks prior to SNM1B, previous 
studies revealed that SNM1B depletion leads to an increase in RPA foci formation after 
aphidicolin treatment 31.  Since RPA binds to ssDNA, these findings suggest that 
SNM1B knockdown may affect the overall levels of ssDNA in cells exposed to 
replication stress.  To assess the levels of ssDNA, control and SNM1B-depleted cells 
were labeled with the thymidine analogue, 5-bromo-2’-deoxyuridine (BrdU), for 24 hours 
to ensure incorporation into both the parental and nascent genomic DNA.  Cells were 
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treated with aphidicolin for 24 hours and fixed using non-denaturing conditions.  
Staining with an anti-BrdU antibody would therefore detect labeled DNA that becomes 
single-stranded and exposed.  Using immunofluorescence microscopy, BrdU staining 
was detected and quantitated as the overall fluorescence intensity within each nucleus 
(Figure 2.3A,B).  We observed that a subset of cells had higher levels of detectable 
ssDNA, therefore the average percentage of cells with high intensity BrdU staining was 
also calculated (Figure 2.3C).  The percentage of cells with high BrdU fluorescence was 
significantly increased after SNM1B depletion compared to non-silencing (NS) controls.  
In untreated and aphidicolin-treated cells, this increase was approximately 4-fold and 2-
fold, respectively (p<0.05; Figure 2.3C).  These findings indicate that SNM1B is 
important for preventing extensive generation of ssDNA at both spontaneous and 
aphidicolin-induced stalled forks.  
SNM1B facilitates the restart of stalled replication forks 
 If stalled forks are aberrantly processed, then replication cannot restart and 
proceed in a timely manner.  The accumulation of ssDNA in SNM1B-depleted cells 
suggests that replication intermediates may be unstable and hyper-resected.  Several 
DNA repair factors have been implicated in protecting forks from excessive nucleolytic 
degradation, thereby promoting efficient recovery and restart 41,42,11.  To determine if 
SNM1B facilitates replication fork stability and restart, we utilized the established DNA 
fiber assay.  In this assay, progressing replication forks can be sequentially labeled 
using incorporation of thymidine analogs, specifically iodo-deoxyuridine (IdU) and 
chloro-deoxyuridine (CldU).  The resulting DNA tracts can then be visualized by 
fluorescent microscopy after immunostaining of each analog.  DNA fibers that are able 
to incorporate both analogs are considered “ongoing” forks (red to green), whereas 
tracts that only incorporate IdU are described as “stalled or terminated” forks (red only).  
Alternatively, “new” replication forks are represented by DNA tracts that only incorporate 
CldU (green only) (Figure 2.3D).     
 In unperturbed conditions, SNM1B-depleted cells displayed an approximately 4-
fold increase in stalled replication forks and a 1.3-fold decrease in ongoing forks 
compared to the NS controls (p<0.001; Figure 2.3E).  The percentage of newly initiated 
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replication forks remained unchanged between the SNM1B-depleted cells and the 
controls (Figure 2.3E).  These findings demonstrate that SNM1B is required for the 
recovery and restart of spontaneously stalled forks and that it is dispensable for 
initiating new origin firing.  
SNM1B prevents the accumulation of DSBs at stalled forks and promotes RAD51 
filament formation  
 DSBs are often formed as DNA intermediates in the processing of stalled or 
collapsed replication forks.  The histone variant, H2AX, is phosphorylated by both ATM 
and ATR in response to DSBs and stalled replication forks 43,44.  Although 
phosphorylated H2AX (gH2AX) is generally considered a maker for DSBs, studies have 
shown that gH2AX is present at stalled forks well before DSB formation 45. Previous 
findings from our lab revealed that aphidicolin induces gH2AX foci formation, but that 
SNM1B is dispensable for this process 31.  However, since gH2AX is present at early 
stages of fork stalling, we asked whether these forks are processed into DSBs by 
examining the colocalization of gH2AX and 53BP1, an important regulator in the 
response to DSBs.  In both untreated and aphidicolin-treated cells, the percentage of 
gH2AX and 53BP1 colocalization was increased approximately 2-fold upon SNM1B-
depletion compared to the controls (p<0.05, p<0.001; Figure 2.4A).  This suggests that 
SNM1B is important for preventing an accumulation of DSBs at stalled replication forks.   
The DSBs that result from replication fork collapse are repaired through HR, 
which involves the recruitment and coordination of FANCD2, BRCA1/2, and RAD51, 
among others.  In response to both ICLs and aphidicolin-induced stress, SNM1B is 
required for proper localization of FANCD2 and BRCA1 27,31.  SNM1B also promotes 
RAD51 filament formation after ICL damage 30.  Therefore, SNM1B may be involved in 
the downstream processing of DSBs at replication forks.  To examine this further, we 
assessed the impact of SNM1B depletion on RAD51 foci formation upon exposure to 
aphidicolin.  After 24 hours of aphidicolin treatment, the SNM1B-deficient cells showed 
a significant 2.5-fold decrease in RAD51 foci formation compared to the controls 
(p<0.05; Figure 2.4B).  This finding provides further evidence for a role of SNM1B in 
DSB repair at stalled forks by promoting RAD51 filament formation at these sites. 
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HR-mediated repair at Tus/Ter-stalled forks 
 The precise molecular events that occur during HR at a collapsed replication fork 
remain to be fully elucidated.  The use of DNA damaging agents to induce replication 
stress have been informative in understanding this process, but they can often cause 
multiple types of lesions at various sites throughout the genome, making some findings 
difficult to interpret.  For example, ionizing radiation (IR) is mostly used to study the 
response to DSBs, but it can also induce single-strand breaks and base damage.  
Additionally, cisplatin can generate a myriad of DNA adducts, such as DNA intra- and 
interstrand crosslinks, monoadducts, and DNA-protein crosslinks 46. Therefore, assays 
have been developed to provide a more detailed and controlled analysis of events that 
occur at a single perturbed replication fork within a specific location of the genome.  
One such method utilizes the Escherichia coli Tus/Ter complex to induce site-specific 
fork stalling and HR in mammalian cells.  In most bacterial species, bidirectional 
replication of the circular chromosome terminates when the forks converge at a site 
opposite of the origin.  This region contains multiple 23bp terminator sequences (Ter), 
which are bound by the protein Tus to induce polar replication fork trapping.  Tus/Ter 
binding forms a barrier to replication fork progression and results in replication 
termination 47,48.  Tus/Ter has been previously used to examine recombination events 
after fork collapse and provided direct evidence that BRCA1, BRCA2, and RAD51 
regulate HR at stalled forks 49.  Since we have shown that SNM1B is involved in the 
localization of some of these factors to sites of replication stress, we asked whether 
SNM1B might also be important for regulating recombinational repair.   
To examine the specific role of SNM1B in the recombination events that occur as 
a result of replication fork collapse, we used the previously described Tus/Ter reporter 
system 49 (Figure 2.5D).  This reporter was targeted as a single copy to the 
ROSA26 locus of the mouse embryonic stem (mES) cell line 11CO/47T (Brca1fl/BRCT).  It 
contains two tandem enhanced green fluorescent protein (GFP) genes, one truncated at 
its 5’ end (5’ TR-GFP) and the other interrupted by 6xTer sequences adjacent to an I-
SceI restriction enzyme cut site (6xTer-I-SceI-GFP) 49.  The E. coli terminator protein, 
Tus, can specifically bind to the 6xTer sequences to form a Tus/Ter complex that 
causes bidirectional replication fork stalling.  When these stalled forks are processed, 
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DSBs are generated and repaired through HR.  Recombination between the broken 
GFP copy and the 5’-truncated GFP of the sister chromatid restores wildtype GFP 
expression.  During gene conversion, nascent strand synthesis can extend for short 
distances (short tract gene conversion – STGC) or for several kilobases (long tract gene 
conversion – LTGC) prior to termination.  LTGC is considered to be error-prone and 
often results in tandem gene duplication.  LTGC is differentiated from STGC in this 
reporter by the duplication of a red fluorescent protein (RFP) gene cassette.  Two 
artificial exons of RFP (“A” and “B” in Figure 2.5D) were placed in an inverted 
orientation between the two copies of GFP, and upon duplication, splicing between 
exon A of the first cassette and exon B of the second generates wildtype RFP.  
Therefore, STGC products are GFP+RFP- and LTGC products are GFP+RFP+.  
Additionally, a bias towards error-prone LTCG can be evaluated based on 
GRP+RFP+/Total GFP+ calculations. 
SNM1B was depleted in mES cells containing the Tus/Ter reporter, and Tus was 
expressed to induce site-specific replication fork stalling (Figure 2.5A-C).  There was an 
approximately 2-fold reduction in total HR and Tus-induced STGC in SNM1B-deficient 
cells compared to NS controls (p<0.001; Figure 2.5E,F).  Tus-induced LTGC was also 
reduced in SNM1B-depleted cells compared to the control, however the loss of SNM1B 
did not significantly bias HR in favor of LTGC (Figure 2.5F).  These data indicate that 
SNM1B is involved in the recombination events at collapsed replication forks, but does 
not significantly influence the balance between STGC and LTGC. 
Discussion 
 The processing of stalled replication forks must be tightly controlled to allow for 
the appropriate timing and extent of DNA digestion at intermediate structures.  Since 
SNM1B is a key DNA nuclease involved in the resolution of stalled forks, we first 
examined whether it was regulated in a way to ensure its activity was limited to S-phase 
when DNA replication occurs.  We used a double thymidine block and Hoechst sorting 
to determine if SNM1B protein levels were cell cycle regulated.  Interestingly, SNM1B 
was stabilized in S-phase in response to the double thymidine block, but there was no 
significant change in SNM1B protein levels throughout G1-, S-, or G2/M-phases in 
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unperturbed cells.  This suggests that SNM1B is not regulated by the cell cycle, but is 
potentially stabilized by agents that induce replication stress.  It is necessary to 
determine whether this form of regulation occurs at the protein level, as opposed to 
changes in transcription or translation.  Since SNM1B in our current study is expressed 
from a constitutive CMV promoter, we expect transcript levels to be unaltered, however 
we cannot rule out the possibility that changes in protein levels are due to translational 
control.  Intriguingly, the nuclease CtIP, which also displays elevated levels during S-
phase, has been shown to be regulated by the Serpine mRNA binding protein 1 
(SERBP1) at the translational level.  SERBP1 binds to CtIP mRNA and is required for 
translational induction of CtIP in S-phase, without affecting the synthesis or stability of 
CtIP mRNA 50.  Additionally, a number of DNA repair factors, including MRE11, were 
found to be under translational control throughout the cell cycle in a genome-wide 
ribosome profiling study 51.  Cyclin A2 has been described to upregulate MRE11 
expression by binding to its mRNA and promoting translation 52.  Thus, SNM1B may be 
regulated in a similar way during S-phase, but this requires further exploration. 
In addition to the double thymidine block, SNM1B protein levels are also 
stabilized in response to aphidicolin treatment and become highly associated with 
chromatin.  It is possible that the increased chromatin association of SNM1B after 
aphidicolin exposure may aid in its stabilization during S-phase.  It would be interesting 
to examine the effects of other DNA damage-inducing agents on SNM1B protein levels 
in order to better understand its regulation.   
SNM1B has been shown to form subnuclear foci in response to aphidicolin-
induced replication stress, but the role of other DNA repair proteins on its recruitment to 
these sites is unknown 31.  Therefore, we examined the localization of SNM1B to stalled 
forks relative to both early-response proteins, RPA and MRE11, as well as downstream 
factors, such as FANCD2.  We determined that SNM1B is recruited to aphidicolin-
induced stalled forks after RPA and MRE11, but before FANCD2.  These findings 
indicate that SNM1B is not involved in the early response to stalled replication forks, but 
may function at an intermediate or late stage within the repair process.  Interestingly, 
previous data showed that MRE11 is required for efficient recruitment of 
monoubiquitinated FANCD2 and CtIP to stalled forks 41.  This prompted us to examine 
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the role of MRE11 in the localization of SNM1B to chromatin.  We found that, unlike 
FANCD2 and CtIP, the exonuclease activity of MRE11 was not required for recruitment 
of SNM1B to chromatin after 6 or 24 hours of aphidicolin treatment.  This suggests that 
upon both fork stalling and potentially collapse, SNM1B and MRE11 may localize 
independently from one another, but are both still required for FANCD2 recruitment 31.  
However, since SNM1B and MRE11 have been reported to interact, we cannot 
eliminate the possibility that the MRE11 protein itself is important for SNM1B 
localization.     
Although the MRE11 nuclease activity is not essential for SNM1B recruitment to 
stalled forks, it has been reported to be involved in the nucleolytic processing of DNA 
intermediates after fork regression.  If not properly regulated, excessive degradation by 
MRE11 can result in fork instability.  The HR factors, BRCA1 and FANCD2, have been 
implicated in stabilizing and protecting the fork from excessive degradation by MRE11 
10,11,52.  Since SNM1B is required for the proper recruitment of BRCA1 and FANCD2, we 
asked whether SNM1B depletion affects the levels of ssDNA at stalled forks 31.  We 
found that SNM1B-deficient cells displayed a significant increase in the levels of ssDNA 
compared to controls in both untreated and aphidicolin-treated conditions.  This 
observation indicates that SNM1B may be important for preventing excessive 
nucleolytic processing by MRE11, potentially through recruitment of members of the 
FA/BRCA network.  Defects in the stabilization of stalled forks can prohibit proper 
restart and replication progression.  Analyses of replication fork dynamics revealed that 
SNM1B is required for replication restart in unperturbed cells.  Therefore, loss of 
SNM1B can lead to excessive ssDNA formation and instability at stalled forks, resulting 
in inefficient replication restart. 
RAD51 is another HR factor that has been implicated in the stabilization of 
stalled forks by preventing excessive nascent DNA resection 10,11.  Previous reports 
have also shown that RAD51 can localize to chromatin in the absence of fork stalling 
and at early stages of fork repair, before DNA DSBs are generated 53.  To examine 
whether SNM1B is involved in the localization of RAD51 to stalled forks, we assessed 
RAD51 foci formation in SNM1B-depleted cells.  We found that the percentage of cells 
with RAD51 foci significantly decreases upon SNM1B knockdown compared to the 
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controls.  RAD51 foci formation requires several kilobases of single-stranded DNA, 
therefore these results could suggest that RAD51 coats the excessive ssDNA tracts that 
form upon fork stalling and reversal 54.  However, studies have revealed that the RAD51 
accumulation at stalled forks induced by a protein complex barrier was restricted to 
within a few hundred base pairs of DNA 55.  Therefore, it is more likely that the RAD51 
foci formation that we observe is in response to DNA DSBs generated from collapsed 
replication forks.  Consistent with this hypothesis, we also detected an increase in 
colocalization of gH2AX and 53BP1 foci after SNM1B depletion.  Together, these results 
indicate that SNM1B may be involved in preventing excessive nucleolytic processing at 
stalled forks that result in instability and DSB accumulation. 
Our findings support the notion that SNM1B does not aid in generating the DSBs 
at collapsed forks, but might be important for the processing events for HR-mediated 
repair.  To examine the role of SNM1B in recombination, we used the Tus/Ter reporter 
system and analyzed gene conversion events after site-specific fork stalling.  SNM1B-
depleted cells displayed an overall decrease in HR compared to controls, which is 
similar to previous findings that SNM1B is required for the repair of I-SceI-induced 
DSBs 30.  Additionally, we found that there was a reduction in both STGC and LTGC 
products after SNM1B knockdown, with the decrease in STGC being statistically 
significant.  There was also no significant bias of HR towards LTGC in SNM1B-depleted 
cells compared to the controls.  Other members of the FA/BRCA pathway, including 
BRCA1, BRCA2, RAD51, and FANCP/SLX4, have all been shown to positively regulate 
STGC after Tus/Ter-induced fork stalling 49.  SNM1B has been reported to interact with 
the nuclease scaffold, FANCP/SLX4, and we have demonstrated that it is necessary for 
recruitment of BRCA1 and RAD51 to sites of replication stress 31.  Therefore, SNM1B 
may function with these repair factors to aid in the processing events after replication 
fork collapse.  
Previous studies have demonstrated that Tus/Ter-induced HR entails 
bidirectional fork arrest and that STGC products are the result of canonical synthesis-
dependent strand annealing (SDSA) of two DSB ends 49.  The termination mechanism 
of Tus/Ter-induced LTGC products is unknown, but involves extensive nascent strand 
synthesis that often results in gene duplication.  Unlike BRCA1 and RAD51, SNM1B 
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does not significantly suppress LTGC at stalled forks.  These data reveal that SNM1B 
may be necessary for the initiation of HR-mediated repair after fork collapse, but has a 
more minor role in the termination mechanism of gene conversion.  Since the mES cell 
line used for this study can express a mutant form of BRCA1, it would be interesting to 
assess if SNM1B and BRCA1 are epistatic in their functions of HR-mediated repair at 
collapsed forks.   
 In conclusion, we demonstrate that SNM1B has critical roles during the resolution 
of replication stress by promoting replication fork recovery and repair.  SNM1B functions 
at a later stage in the repair process to prevent excessive ssDNA intermediates, 
facilitate RAD51 recruitment, and repair DSBs after fork collapse.  Our findings have 
provided mechanistic insights into the role of SNM1B in avoiding detrimental replication-
associated genome instability.  
Materials and Methods 
Generation of Cell Lines  
A previously described pLL-IRES-GFP lentiviral vector harboring siRNA-resistant 
SNM1B cDNA was used to generate HCT116 stable cell lines 30.  This SNM1B cDNA 
contains a C-terminal V5 epitope tag, and an empty vector (EV) was used as a control.  
Lentiviruses were generated by co-transfecting the lentiviral constructs with packaging 
plasmids pLP1, pLP2, and pVSVG (Invitrogen) into 293T cells using calcium phosphate.  
The viral supernatants were collected after 48 hours and filtered through 0.45mm PVDF 
filters (Millipore).  HCT116 cells were transduced with 1 ml viral media containing 
4μg/ml polybrene and 1 ml culture media supplemented with 10% FBS for 24 hours.  
Cells were harvested 24 hours later, and expression of the SNM1B-IRES-GFP cassette 
was determined by flow cytometry.  GFP-positive cells were sorted (UM Flow Cytometry 
Core) to increase the percentage of cells expressing SNM1B within the population. 
Knockdown of SNM1B expression by siRNA 
HCT116 cells were plated in 6-well or 12-well plates 24 hours prior to 
transfection.  All siRNAs (50nM) were transfected using Lipofectamine 2000 (Invitrogen) 
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as per the manufacturer’s instructions.  Knockdown of mSnm1B for the recombination 
assay is described below. To verify the extent of knockdown, SNM1B mRNA levels 
were determined via semi-quantitative RT-PCR.  The target sequences for siRNA 
depletion were as follows: Human siSNM1B: 5′-CCTCTTGCATCGTCACCTACATT-3′; 
Mouse siSnm1B: 5’-CACTGCTTGCCTCTTGCATCG-3’; NS siRNA (Qiagen AllStars 
Negative Control) was used as the non-silencing control.  
Semi-quantitative RT-PCR 
Total RNA (1μg) isolated from cells was reverse transcribed using a poly-dT(20) 
primer and murine leukemia virus-reverse transcriptase (Invitrogen).  Human cDNA was 
amplified using SNM1B-specific primers located in the 3’UTR and exon 3, and mouse 
cDNA was amplified using primers located in exons 3 and 4. GAPDH was amplified as a 
control.  Bands were quantitated using ImageJ, and SNM1B cDNA levels were 
normalized to GAPDH.   
Cell Synchronization and Cell Cycle Analyses 
 For the double thymidine block, HCT116 cells stably expressing WT SNM1B-V5 
were treated with 2mM thymidine for 18 hours, released into fresh media for 6 hours, 
and exposed to 2mM thymidine for an additional 18 hours.  After washing with PBS, 
cells were released from the double thymidine block and harvested at 0, 2, 4, and 6 
hours for cell cycle analysis and immunoblotting. 
To examine cell cycle profiles after synchronization, cells were fixed with cold 
70% ethanol, stored at -20°C, and stained with a solution containing 50μg/ml propidium 
iodide, 50μg/ml RNase A, and 0.1% Triton X-100 for 30 minutes at room temperature.  
Cells were analyzed using an Accuri C6 flow cytometer and FlowJo software. 
Western Blot Analyses 
Cells were harvested and lysed on ice for 1 hour in CSK buffer (10mM PIPES pH 
6.8, 100mM NaCl, 300mM sucrose, 1mM MgCl2, 0.1% Triton X-100) containing 
protease inhibitors (Roche Complete Mini EDTA-
 
54 
PhosSTOP), and benzonase (Sigma).  Lysates were centrifuged at 14,000 RPM for 20 
min and protein concentrations were determined using the Bradford assay (BioRad).  
Cell extracts were resolved by SDS-PAGE and transferred following standard 
procedures.  Proteins were analyzed using the appropriate primary and secondary 
antibodies, and bands were visualized and quantitated using Li-Cor Odyssey 2.1 
software and ImageJ. 
The following primary antibodies were used:  V5 (Invitrogen); MRE11 (Cell 
Signaling); FANCD2 (Novus Biologicals); CtIP (Bethyl); Cyclin B1 (Santa Cruz); Cyclin 
A (Santa Cruz); H2AX (Millipore); GAPDH (Cell Signaling and Santa Cruz).  Secondary 
antibodies were IRDye conjugated goat anti-rabbit or anti-mouse IgG (Li-Cor 
Biosciences). 
Hoechst Staining and Cell Sorting 
HCT116 cells stably expressing WT SNM1B-V5 were suspended at 1.5 x 106 
cells/ml in McCoy’s medium containing 2% FBS.  Cells were incubated with Hoechst 
dye at a final concentration of 5μg/ml for 30 min or 6μg/ml for 90 min at 37°C with 
intermittent shaking.  Fluorescence-activated cell sorting (FACS) was performed to sort 
the cells into G1-, S-, and G2/M-phase populations based on DNA content.  Cells were 
lysed and immunoblotting was used to assess WT SNM1B-V5 protein levels in each 
phase of the cell cycle.  The average level of SNM1B protein was calculated from three 
independent experiments.  
Immunofluorescence of Subnuclear Foci 
HCT116 cells stably expressing WT SNM1B-V5 were grown on glass coverslips 
in 12-well plates and treated with 0.3μM aphidicolin for 1, 2, 4, 6, or 24 hours.  For 
knockdown experiments, HCT116 cells were grown on glass coverslips in 12-well plates 
and transfected with NS or siSNM1B siRNAs. At 48 hours post-transfection, cells were 
treated with 1µM or 2µM aphidicolin for 24 hours.  For RPA, MRE11, FANCD2, and 
gH2AX:53BP1 foci, cells were incubated in cold extraction buffer (20mM HEPES, 50mM 
NaCl, 300mM sucrose, 3mM MgCl2, 0.5% TX-100) for 5 min followed by fixation in 3% 
paraformaldehyde/2% sucrose for 20 min.  For SNM1B-V5 foci, cells were fixed in ice-
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cold 70% methanol/30% acetone for 20 min at -20°C and air-dried at room temperature.  
For RAD51 foci, cells were fixed in a solution containing 3% paraformaldehyde, 2% 
sucrose, and 0.5% Triton X-100 for 20 min.    
After fixation and permeabilization, cells were stained with the following primary 
antibodies for 45 min at room temperature or overnight at 4°C (for RAD51): RPA 
(Calbiochem); MRE11 (Novus Biologicals); FANCD2 (Novus Biologicals); V5 
(Invitrogen); gH2AX (Millipore); 53BP1 (Novus Biologicals); RAD51 (GeneTex).  
Cells were stained with anti-IgG Alexa Fluor 488 or 594 (Invitrogen Molecular 
Probes) secondary antibodies for 45 min and coverslips were mounted on slides using 
ProLong Gold Antifade Reagent with DAPI (Life Technologies).  Images were acquired 
using an Olympus BX61 microscope and FISHview software (Applied Spectral 
Imaging).  Approximately 100 cells per sample were scored from at least three 
independent experiments. 
Cellular Fractionations 
HCT116 cells stably expressing WT SNM1B-V5 were treated with 50μM mirin 
(Cayman Chemical) and 1µM aphidicolin for the indicated times.  Cells were harvested 
and pellets were first resuspended in fractionation buffer I (50mM HEPES pH 7.5, 
150mM NaCl, 1mM EDTA, 0.2% NP-40, supplemented with protease and phosphatase 
inhibitors) for 5 min on ice.  After centrifugation at 1000 × g for 5 min, the supernatant 
was collected (cytoplasmic fraction), and the pellets were washed with fractionation 
buffer I.  The nuclear pellets were then lysed for 40 min on ice with fractionation buffer II 
(50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA, 0.5% NP-40, supplemented with 
protease and phosphatase inhibitors).  The supernatants were collected (nuclear 
faction) after centrifugation at 16,000 × g for 15 min. The final pellets were lysed in RIPA 
buffer (50mM Tris-HCl pH 8.0, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS, supplemented with protease and phosphatase inhibitors), sonicated, and 
cleared by centrifugation at 16,000 × g for 20 min (chromatin fraction).  The whole cell 
extracts (WCEs) were prepared in a similar manner as the chromatin fractions.  Equal 
concentrations of each fraction were analyzed by immunoblotting, with GAPDH and 
H2AX serving as controls for cytoplasmic and chromatin fractions, respectively.
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ssDNA Immunofluorescence Assay 
HCT116 cells were grown on glass coverslips in 12-well plates and transfected 
with NS or siSNM1B siRNAs for 48 hours.  Cells were labeled with 20µM BrdU for 24 
hours and treated with 1µM Aphidicolin for an additional 24 hours.  Using non-
denaturing conditions, cells were incubated in cold extraction buffer (20mM HEPES, 
50mM NaCl, 300mM sucrose, 3mM MgCl2, 0.5% Triton X-100) for 5 min and then fixed 
with 3% paraformaldehyde/2% sucrose for 20 min.  Cells were incubated with an anti-
BrdU antibody (BD Pharmigen) followed by an anti-IgG Alexa Fluor 488 secondary 
antibody to visualize BrdU staining.  Images were acquired with an Olympus BX61 
microscope and FISHview Software. The fluorescence intensity for every nucleus was 
measured and normalized to background levels for each experiment. At least three 
independent experiments were performed and approximately 100 cells were analyzed 
per condition.   
DNA Fiber Assay 
HCT116 cells were transfected with NS or siSNM1B siRNAs for 48 hours and 
labeled with 50µM IdU for 20 min followed by 100µM CldU for 20 min.  Cells were 
resuspended at 200 cells/µl in ice-cold PBS and 2µl of the cell suspension was 
deposited on a silanized slide (Sigma).  Approximately 15µl of lysis buffer (200mM Tris 
pH 7.4, 0.5% SDS, 50mM EDTA) was added to the cells for 10 min, and the slides were 
tilted to 15° to stretch the DNA fibers. After air-drying for 6-8 hours, slides were fixed in 
methanol:acetic acid (3:1) for 2 min, dried overnight in the dark, and placed at -20°C for 
24 hours.  The DNA was denatured with 2.5M HCl for 30 min and stained with mouse 
anti-IdU (BD Biosciences) and rat anti-CldU (AbD Serotec) primary antibodies.  To 
visualize fibers using immunofluorescence microscopy, cells were stained with anti-IgG 
Alexa Fluor 594 and 488 secondary antibodies and imaged with an Olympus BX61 
microscope and FISHview software.  Approximately 200 fibers were scored for each 
sample from at least three independent experiments.  For scoring, red to green tracts 
were categorized as ongoing forks, red only tracts as stalled forks, and green only tracts 
as new forks.  The average percentage of new forks (or ongoing forks) was calculated 
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as the number of new forks (or ongoing forks) divided by the total number of ongoing, 
stalled, and new forks combined. 
Recombination Assays 
The Brca1fl/BRCT mouse embryonic stem (mES) cell line harboring a single copy of 
a 6xTer/HR reporter at the ROSA26 locus was generated and cultured as previously 
described 49.  The mES cells were grown on MEF feeders for approximately one week 
before they were depleted of MEFs twice over the course of two hours.  Cells were then 
alternately passaged and conditioned on gelatinized plates for use in recombination 
assays.  
Mouse ES cells (1.6 x 105) were transfected in suspension with 20pmol siRNA 
and 0.35μg pcDNA3β-mycNLS-Tus or control vector using Lipofectamine 2000.  Two 
transfected wells of a 24-well plate were pooled for each condition, and GFP+RFP- and 
GFP+RFP+ frequencies were scored 3 days post-transfection by flow cytometry.  
Approximately 1.5 x 106  total events were scored per sample, and values were 
corrected for background events and transfection efficiency.  Transfection efficiency 
was measured simultaneously by parallel transfection with 0.035μg of wild-type GFP 
expression vector, 0.315μg control vector, and 20pmol siRNA.  Data represent the 
mean and SEM of four independent experiments.   
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Figure 2.1 SNM1B protein levels in unperturbed cells and after S-phase 
synchronization 
(A) WT SNM1B HCT116 cells were released from a double thymidine block for the 
indicated amounts of time and collected for propidium iodide staining and Western blot 
analysis.  Representative cell cycle profiles and Western blot are shown.  SNM1B 
protein levels were quantitated and plotted relative to the asynchronous control.  
Results are represented as the mean ± SEM from five independent experiments. 
(B) WT SNM1B HCT116 cells were incubated with Hoechst dye and sorted using 
FACS.  Sorted cells were lysed for Western blot analysis and protein levels were 
quantitated relative to the amount in G1-phase.  Results are represented as the  
mean ± SEM from three independent experiments.    
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Figure 2.2 SNM1B localization to stalled forks occurs after MRE11 and is 
independent of MRE11 exonuclease activity 
(A) WT SNM1B HCT116 cells were treated with 0.3μM aphidicolin for the indicated 
times, fixed, and stained for visualization of SNM1B-V5, RPA, MRE11, and FANCD2 
subnuclear foci.  Representative images are shown for each protein throughout the 
timecourse. (B) The percentage of foci-positive cells was quantitated and plotted as the 
mean ± SEM.  Approximately 100 cells were analyzed from at least three independent 
experiments. (C) WT SNM1B HCT116 cells were pre-treated with 50μM mirin for 1 hr 
and 1μM aphidicolin was added for an additional 6 hrs.  Cells were fractionated and 
protein levels were assessed via Western blot. The L and S labels represent the 
monoubiquitinated and unmodified forms of FANCD2, respectively. The asterisk marks 
the band for CtIP. WCE, whole cell extract; Aph, Aphidicolin 
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Figure 2.3 SNM1B prevents the accumulation of ssDNA at stalled forks and 
facilitates fork restart 
(A) HCT116 cells transfected with NS or siSNM1B siRNAs were allowed to incorporate 
BrdU for 24 hrs to label parental and nascent DNA.  Cells were treated with 1μM 
aphidicolin for 24 hrs, fixed, and stained with an anti-BrdU antibody in non-denaturing 
conditions to visualize ssDNA.  Representative images are shown. (B) The normalized 
BrdU fluorescence intensity of every nucleus was plotted along with the mean ± SEM. 
*p<0.001 (C) The average percentage of cells with high intensity BrdU staining (>2.5 
fluorescence intensity) was plotted ± SEM.  Approximately 100 cells were analyzed from 
at least three independent experiments. *p<0.05 (D) HCT116 cells transfected with NS 
or siSNM1B were incubated with 50µM IdU for 20 min (red), washed, incubated with 
100µM CldU for 20 min (green), and then lysed on silanized slides. DNA fibers were 
spread by gravity, denatured, and visualized by immunofluorescence.  Representative 
DNA fiber images of ongoing, stalled, and new forks are shown. (E) The average 
percentage of each fork type is plotted ± SEM.  Approximately 200 fibers were analyzed 
from at least three independent experiments. ***p<0.001; Unt, Untreated; Aph, 
Aphidicolin 
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Figure 2.4 SNM1B prevents the accumulation of DNA DSBs and promotes RAD51 
filament formation 
(A) HCT116 cells transfected with NS or siSNM1B siRNAs were treated with 1µM 
aphidicolin for 24 hrs, fixed, and stained for gH2AX and 53BP1 foci colocalization.  The 
percentage of cells with >10 foci was quantitated and plotted as the mean ± SEM. 
*p<0.05, ***p<0.001 (B) HCT116 cells transfected with NS or siSNM1B siRNAs were 
treated with 2µM aphidicolin for 24 hrs, fixed, and stained for RAD51 subnuclear foci.  
Representative foci images are shown.  The percentage of cells with >5 RAD51 foci 
was quantitated and plotted as the mean ± SEM. Approximately 100 cells were 
analyzed from at least three independent experiments. *p<0.05; Unt, Untreated; Aph, 
Aphidicolin 
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Figure 2.5 SNM1B is required for the efficient repair of Tus/Ter-induced stalled 
replication forks 
(A) Diagram of mSnm1B cDNA with locations of the siSnm1B siRNA (msi-1) target site 
and RT-PCR primers (arrows). (B) A representative gel of RT-PCR products from mES 
cells transfected with NS or msi-1 siRNAs. Gapdh was used for normalization of cDNA 
levels. RT, Reverse Transcriptase (C) RT-PCR bands were quantitated using ImageJ 
and levels were plotted relative to NS controls. Results are represented as the mean ± 
SEM from four independent experiments. (D) Schematic describing the reporter system 
for Tus/Ter-induced fork stalling.  The reporter contains a 5’ truncated copy of GFP, two 
inverted artificial exons of RFP, and GFP interrupted by an I-SceI endonuclease site 
and 6 copies of the bacterial replication terminator sequence (Ter). Expression of the 
Tus protein, which binds to Ter sequences, causes replication fork stalling.  After 
collapse, these forks are processed by homologous recombination to produce either 
short- or long-tract gene conversion products (STGC and LTGC).  wtGFP expression is 
restored in both outcomes, whereas wtRFP expression is only restored from LTGC 
products after proper exon splicing. Image adapted from Willis and Scully, 2016. 56 
(E and F) mES cells harboring a single copy of the 6xTer/HR reporter were transfected 
with a Tus expression vector and NS or siSnm1B siRNAs.  GFP+ RFP- and GFP+RFP+ 
frequencies were scored 72 hrs post-transfection by flow cytometry.  Data represent the 
mean ± SEM of four independent experiments. *p<0.001   
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Figure 2.S1 Semi-quantitative RT-PCR and expression of SNM1B 
(A) Diagram of hSNM1B cDNA with locations of the siSNM1B siRNA (si-1) target site 
and RT-PCR primers (arrows). (B) A representative gel of RT-PCR products from empty 
vector (EV) or WT SNM1B HCT116 cells transfected with NS or si-1 siRNAs. GAPDH 
was used for normalization of cDNA levels. RT, Reverse Transcriptase 
(C) Representative Western blot of WT SNM1B and EV HCT116 protein lysates.  
(D) Representative Western blot of lysates from WT SNM1B HCT116 cells transfected 
with NS or siSNM1B siRNAs. 
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Figure 2.S2 SNM1B is stabilized and enriched on chromatin after aphidicolin 
treatment 
WT SNM1B HCT116 cells were treated with 1µM aphidicolin for 24 hrs, fractionated, 
and protein levels were assessed via Western blot. The L and S labels represent the 
monoubiquitinated and unmodified forms of FANCD2, respectively. The asterisk marks 
a potentially shifted band for SNM1B-V5. WCE, whole cell extract 
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Figure 2.S3 MRE11 exonuclease activity is not required for the chromatin 
association of SNM1B  
WT SNM1B HCT116 cells were pre-treated with 50μM mirin for 4 hrs and 1μM 
aphidicolin was added for an additional 24 hrs.  Cells were fractionated and protein 
levels were assessed via Western blot. The L and S labels represent the 
monoubiquitinated and unmodified forms of FANCD2, respectively. The asterisk marks 
the band for CtIP. WCE, whole cell extract 
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Chapter 3 
Regulation and Post-Translational Modification of SNM1B 
 
Abstract 
 Proteins that function in the DNA damage response often have roles in multiple 
pathways or respond to diverse forms of DNA damage.  One such factor is the DNA 
nuclease, SNM1B, which has known functions in DNA interstrand crosslink repair, 
double-strand break repair, telomere maintenance, and the resolution of stalled 
replication forks.  However, the precise control of SNM1B within these processes is not 
well understood.  We sought to identify the mechanisms underlying the regulation of 
SNM1B and its functions within the cell cycle.  SNM1B depletion results in decreased 
cellular survival to spindle stress, suggesting a potential role for SNM1B in mitosis.  We 
determine that SNM1B is phosphorylated during G2/M-phases on its C-terminal residue 
S481.  We also show that SNM1B phosphorylation is dispensable for its localization and 
binding to the telomere protein, TRF2, but supports protein stability by preventing 
polyubiquitination during mitosis.  Together, these data reveal novel mechanisms for the 
regulation of SNM1B throughout the cell cycle.  
 
 
Jordann Smak designed and performed the experiments for all figures.
 
75 
Introduction 
Maintenance of genome stability is critical to ensure normal cell growth and 
division.  It relies on the precise control of DNA replication, DNA repair, and 
chromosome segregation and their proper integration with cell cycle progression.  The 
cell cycle is intimately linked with genome protection, as the propagation of DNA 
damage into mitosis can result in chromosomal aberrations and aneuploidy.  In addition, 
the DNA repair pathway choice is partly dictated by the cell cycle phase and type of 
damage encountered 1,2.  Proteins that function in the DNA damage response (DDR) 
often have multiple roles within various repair processes, many of which occur at 
different stages during cell division.  Therefore, these factors must be tightly regulated 
to ensure their timely activation and recruitment for repair.  
Most processes of the DDR have been extensively studied in S-phase, since this 
is the phase in which the bulk of DNA replication occurs.  The DNA nuclease, SNM1B, 
is one DDR protein that has been implicated in facilitating the resolution of stalled 
replication forks during S-phase.  SNM1B is a member of the metallo-β-
lactamase/βCASP family of proteins and possesses 5’ to 3’ exonuclease activity 3.  
SNM1B localizes to stalled forks and is required for the efficient recruitment of key DNA 
repair factors to sites of replication stress 4,5.  Depletion of SNM1B results in 
hypersensitivity to DNA crosslinking agents and to the DNA polymerase inhibitor, 
aphidicolin 5–7.  These SNM1B-deficient cells also display elevated levels of genome 
instability, including chromosomal breaks at difficult to replicate common fragile sites 
(CFSs) 4–6.  Together, these findings highlight a role for SNM1B during replication fork 
repair, but the mechanisms regulating its functions remain unknown.   
Other DNA nucleases have been described to aid in the resolution of stalled 
replication forks.  The MRE11 nuclease, which has both endo- and exonucleolytic 
activity, functions by resecting DNA at stalled forks to promote signaling and fork restart.  
It also partners with CtIP to facilitate end resection of DNA double-strand breaks (DSBs) 
that can result from fork collapse.  During S- and G2-phase, CtIP protein levels 
increase, and it becomes phosphorylated in order to bind to MRE11 and stimulate DSB 
repair via homologous recombination (HR) 8–10.  Interestingly, CtIP and MRE11 have 
also been shown to impact chromosome segregation during mitosis, as depletion or 
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inhibition of these enzymes leads to defects in spindle assembly and chromosome 
alignment 11.  CtIP phosphorylation is not required for this mitotic function, thereby 
emphasizing the importance of post-translational modifications (PTMs) on regulating the 
various functions of DNA repair proteins in different phases of the cell cycle.   
Another repair factor that has multiple roles within the DDR is the BLM DNA 
helicase.  BLM has been shown to function in replication fork stabilization and repair, in 
the resection and dissolution of HR intermediates, and in chromosome segregation 
through the resolution of intertwined DNA structures called anaphase bridges 12,13.  
Numerous studies have revealed that PTMs play a significant role in fine-tuning its 
functions in these repair processes 14.  The most striking finding is that BLM becomes 
hyperphosphorylated during mitosis 15–17.  BLM is phosphorylated on multiple sites to 
either target it for proteasomal degradation, to maintain checkpoint activation, or to 
stabilize and localize it to anaphase bridges 16–18.  In addition to its phosphorylation 
during mitosis, BLM protein levels are also regulated throughout the cell cycle.  BLM 
becomes stabilized during S-phase and its levels are significantly reduced as cells cycle 
into G1-phase 15.  These changes in protein stability and regulation through PTMs 
correlate with the distinct roles for BLM in different cell cycle phases.   
 Similar to BLM, previous data from Chapter 2 demonstrates that the DNA 
nuclease, SNM1B, also becomes stabilized by agents that induce synchronization in S-
phase.  Therefore, it is possible that SNM1B may be regulated by similar mechanisms 
as BLM to dictate its roles throughout the cell cycle.  Most of the known functions of 
SNM1B are specific to S- and G2-phase, but the growing evidence for mitotic functions 
of other repair proteins, such as CtIP and BLM, prompted us to examine its regulation 
and role in mitosis.    
 We found that SNM1B is important for cellular survival in response to spindle 
stress and that it is phosphorylated during G2-phase and mitosis.  SNM1B 
phosphorylation occurs within its C-terminal domain, specifically on the serine residue 
481.  Investigations using a non-phosphorylatable mutant revealed that phosphorylation 
is dispensable for proper localization of SNM1B, but may promote protein stability by 
preventing polyubiquitination and degradation by the proteasome.  Together, these data 
provide novel insight into the post-translational regulation of SNM1B. 
 
77 
Results 
SNM1B-depleted cells are sensitive to microtubule inhibition 
Although little is known about SNM1B in mitosis, it has been shown to function in 
an early mitotic prophase checkpoint, also known as the antephase checkpoint 19.  
When cells encounter various stresses, such as chromosomal damage and microtubule 
stress, the prophase checkpoint delays commitment to mitosis by preventing or 
reversing chromatin condensation before nuclear envelope breakdown 20.  The metallo-
β-lactamase/βCASP family member, SNM1A, and the ubiquitin ligase, checkpoint with 
FHA and ring finger domains (CHFR), have also been reported to function in the 
prophase checkpoint 21,22.  Interestingly, knockdown of SNM1A and CHFR sensitizes 
cells to microtubule inhibitors 21,23.  A similar phenotype was also observed for cells 
deficient of the Fanconi anemia (FA) protein, FANCA 24.  Since SNM1B functions within 
the FA pathway and participates in the prophase checkpoint, these findings prompted 
us to examine whether SNM1B is important in the response to spindle stress.         
Endogenous SNM1B is expressed at very low levels and is undetectable using 
commercially available antibodies 6,3.  Therefore, we generated HCT116 cell lines stably 
expressing an siRNA-resistant, V5-tagged SNM1B cDNA or an empty vector (EV) as a 
control.  To examine the role of SNM1B in the response to spindle stress, SNM1B was 
knocked down in the HCT116 EV cell line using a previously characterized siRNA and 
treated with nocodazole, a reversible inhibitor of microtubule polymerization that stalls 
cells in prometaphase 4.  After 24 hours, the mitotic shake-off cells were replated at low 
density, and sensitivity to nocodazole was assessed using crystal violet staining of 
surviving colonies.  SNM1B-depleted cells were significantly more sensitive to 
nocodazole treatment compared to the non-silencing (NS) controls, with cellular survival 
reduced to approximately 15% compared to 80% (p<0.01; Figure 3.1A).  This suggests 
that SNM1B may have a functional role during mitosis, specifically in response to 
spindle stress.    
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SNM1B is phosphorylated in G2-phase and mitosis 
The finding that SNM1B is important for survival after nocodazole release 
prompted us to examine the protein dynamics of SNM1B as cells enter G2/M-phases.  
Considering that several DNA repair proteins are phosphorylated in mitosis, we were 
particularly interested in PTMs.  HCT116 cells expressing V5-tagged SNM1B were 
treated with nocodazole to synchronize cells in mitosis, and a prominent, slow-migrating 
band was observed for SNM1B in the Western blot (Figure 3.1B; 3.S1A).  Similar results 
were seen in the osteosarcoma U2OS cell line and in the transformed embryonic kidney 
293T cell line, suggesting that the shift is not cell type-specific or characteristic to 
cancer cells (Figure 3.S1B).  Together, these data provide evidence that SNM1B is 
post-translationally modified during mitosis.   
Protein phosphorylation is a common PTM that serves as a key regulatory 
mechanism during the progression of mitosis.  To determine whether the observed 
modification of SNM1B is phosphorylation, cell lysates were treated with lambda protein 
phosphatase (lPPase), which releases phosphate groups from serine, threonine, and 
tyrosine residues.  The shifted band was eliminated by lambda phosphatase treatment 
and retained with addition of phosphatase inhibitors (Figure 3.1C).  This finding 
indicates that the shifted form of SNM1B during mitosis is due to phosphorylation.  The 
shifted band is also observed in a Phos-tag SDS-PAGE gel, which specifically retards 
the migration of phosphorylated proteins (Figure 3.S1C).  This provides further evidence 
that the modification of SNM1B is phosphorylation.   
To verify that phosphorylation of SNM1B is not solely in response to microtubule 
inhibition, the appearance of the shifted band was examined in unperturbed conditions.  
Cells were sorted into G1-, S-, and G2/M-phases of the cell cycle using Hoechst 
staining and flow cytometry.  SNM1B phosphorylation was more prominent in G2/M- 
compared to G1- or S-phase cells (Figure 3.1D).  We also examined the dynamics of 
phosphorylated SNM1B by synchronizing and releasing cells from a double thymidine 
block, which reversibly stalls cells in early S-phase.  The level of phosphorylated 
SNM1B was lower in thymidine-blocked cells compared to nocodazole-synced cells 
(Figure 3.S1C), and the modified form accumulated as cells were released from the 
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thymidine block into G2/M (Figure 3.1E).  The ratio of modified SNM1B/unmodified 
SNM1B protein was approximately 0.5 when 65% of the cells were in G2/M compared 
to 0.2 when only 10% of the cells were in G2/M (Figure 3.1F).  This supports the finding 
that SNM1B is preferentially phosphorylated in G2/M-phases compared to other stages 
of the cell cycle. 
To verify that SNM1B is phosphorylated in G2-phase in addition to mitosis, cells 
were synchronized using the cyclin-dependent kinase 1 (CDK1) inhibitor, RO3306 
(CDK1i).  This inhibitor is effective against both CDK1/cyclin B and CDK1/cyclin A 
complexes, and it reversibly stalls cells in late G2-phase (Figure 3.S1A) 25.  SNM1B was 
phosphorylated in cells treated with the CDK1 inhibitor for 20 hours, revealing that this 
modification arises as early as late G2-phase (Figure 3.1G).  
Dependence of SNM1B phosphorylation on the ATM, ATR, or DNA-PKcs kinases 
ATM, DNA-PKcs, and ATR are members of the phosphatidylinositol 3-kinase-
related kinase (PIKK) family of serine/threonine kinases which function in DNA repair 
pathways.  ATM acts as an apical activator of the DNA DSB response by controlling 
an extensive signaling network, whereas DNA-PKcs is involved in DSB repair though 
it roles in non-homologous end-joining 26,27.  ATR is also activated by DSBs, but it 
responds to a broader spectrum of DNA damage and plays a central role in the 
response to replication stress 28.  Since SNM1B is a nuclease that functions in the 
response to DNA damage and replication stress, I first examined whether ATM, DNA-
PKcs, or ATR were involved in SNM1B phosphorylation.  Treatment with inhibitors of 
these kinases resulted in no change in the phosphorylation status of SNM1B during 
mitosis (Figure 3.2A,B).  Cells treated with bleomycin or UV were used as controls to 
evaluate successful kinase inhibition (Figure 3.S2A,B).   
ATM, ATR, and DNA-PKcs recognize and phosphorylate a consensus sequence 
of S/TQ, which usually reside in clusters within the protein substrate 29.  SNM1B has 
three S/TQ sites, one of which (S444) was previously reported in a mass spectrometry 
study for identification of ATM/ATR targets 30.  We mutated this serine, along with 
another SQ site (S418), and examined the phosphorylation of SNM1B during mitosis.  
After nocodazole treatment, both serine to alanine mutants displayed a discernable shift 
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in the Western blot, suggesting that these sites are not the major sites for 
phosphorylation (Figure 3.2C).  In concert with the inhibitor data, these findings suggest 
that the DNA repair kinases, ATM, ATR, and DNA-PKcs, are not responsible for the 
observed phosphorylation of SNM1B. 
Dependence of SNM1B phosphorylation on mitotic kinases 
Because the phosphorylation of SNM1B is prominent during late G2-phase and 
mitosis, we investigated the potential role of mitotic kinases in this phosphorylation 
event.  These kinases included CDK1, Aurora A, Aurora B, NEK2, and PLK1.  CDK1 is 
considered the master regulator of mitosis.  Entry into mitosis depends on CDK1 
dephosphorylation and activation, whereas exit from mitosis depends on its deactivation 
as a consequence of cyclin destruction.  CDK1 has been shown to phosphorylate 
several DNA nucleases, including MRE11, CtIP, and EXO1, to regulate DNA end 
resection throughout the cell cycle 31–34.  The Aurora kinase family, polo-like kinase 1 
(PLK1), and NIMA related kinase 2 (NEK2) all play important roles in the progression of 
mitosis.  Aurora A promotes mitotic spindle assembly and centrosome maturation, 
whereas Aurora B functions primarily in chromosome segregation and kinetochore 
attachment 35.  PLK1 is involved in centrosome maintenance, chromosome dynamics, 
and mitotic exit, and NEK2 functions in regulating centrosome architecture 36,37.  PLK1 
and NEK2 have also been shown to phosphorylate DNA repair proteins in various 
cellular processes 24,38,39.   
SNM1B was identified as a potential substrate of Aurora kinases in a 
phosphoproteomic study 40.  Therefore, I first examined the potential role of Aurora B in 
SNM1B phosphorylation.  Cells expressing V5-tagged SNM1B were synchronized with 
nocodazole for 18 hours and treated with the Aurora B inhibitor, ZM447439 (AurBi), for 
an additional 1 hour.  Phosphorylated SNM1B was dramatically decreased upon 
treatment with the Aurora B inhibitor compared to the DMSO-treated control (Figure 
3.2D).  Histone H3 S10 is a known substrate for Aurora B, and its phosphorylation was 
used as a control to ensure successful kinase inhibition. 
I next examined the full panel of mitotic kinase inhibitors to assess their effect on 
SNM1B phosphorylation.  There was no change in phosphorylated SNM1B after 
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treatment with inhibitors against PLK1 or NEK2.  However, similar to Aurora B inhibition, 
phosphorylation of SNM1B was decreased after treatment with Aurora A or CDK1 
inhibitors (Figure 3.2E).  The concentration of inhibitor used to target Aurora A in this 
assay could also potentially inhibit Aurora B 41. Therefore, lower doses were tested and 
found to cause no change in phosphorylated SNM1B (Figure 3.S2C).  These data 
provide evidence that Aurora A, PLK1, and NEK2 are likely not involved in SNM1B 
phosphorylation during mitosis.   
To further investigate the potential role of Aurora B in SNM1B phosphorylation, 
alanine point mutations were generated for several serine or threonine residues that 
reside in Aurora kinase consensus sites within SNM1B (Figure 3.3A).  Some of these 
residues are more evolutionarily conserved than others, and one site does not conform 
to the general consensus sequence for Aurora targets (S311).  This site was chosen 
because it was previously identified as a potential Aurora kinase substrate in a mass 
spectrometry study 40.  HCT116 cells were transiently transfected with plasmids 
expressing the V5-tagged SNM1B point mutants and treated with nocodazole for 18 
hours.  The phosphorylation status of each point mutant was assessed using the Phos-
tag SDS-PAGE system (Figure 3.3B) or traditional SDS-PAGE (Figure 3.3C) followed 
by Western blotting.  None of the examined point mutants altered SNM1B 
phosphorylation during mitosis.  This suggests that SNM1B may not be a direct target of 
Aurora B kinase activity or that SNM1B is phosphorylated at alternative sites by Aurora 
B or other kinases.       
Phosphorylated SNM1B is reduced as cells exit mitosis 
The decrease in SNM1B phosphorylation after Aurora B or CDK1 inhibition could 
suggest a role for these kinases in the indirect phosphorylation of SNM1B.  However, 
there is evidence that demonstrates that Aurora B or CDK1 inhibition can lead to spindle 
assembly checkpoint (SAC) bypass 25,42–44.  The SAC ensures that all chromosomes 
are correctly attached to spindle microtubules before division, and its activation halts the 
metaphase-anaphase transition.  SAC bypass would allow the cells to continue through 
mitosis despite perturbed mitotic spindle formation induced by nocodazole.  As shown in 
cell cycle profiles, prolonged inhibition of Aurora B after SAC activation induces a 
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broadening and decrease in G2/M peak height, indicative of possible SAC bypass 
(Figure 3.S3A).  Therefore, SNM1B phosphorylation could be decreased after Aurora B 
inhibition due to progression through mitosis and the events that take place during this 
process.  One major event that is essential for mitotic exit is the degradation of cyclin B 
by the proteasome 45.  To prevent this degradation process and the resulting mitotic 
progression, cells were treated with the proteasome inhibitor, MG132, in the presence 
or absence of the Aurora B inhibitor after SAC activation.  Cell cycle profiles reveal that 
Aurora B inhibition reduced G2/M peak height, whereas the profiles remain unaltered in 
samples treated with MG132 (Figure 3.S3B).  In the Western blot analysis, SNM1B was 
still phosphorylated when mitotic cells were treated with MG132 alone or in combination 
with AurBi (Figure 3.4A).  The same was observed for co-treatment of mitotic cells with 
MG132 and CDK1i (Figure 3.S3C).  This suggests that proteasome inhibition prevents 
the loss of phosphorylated SNM1B.  In addition, treatment with the CDK1i or AurBi 
without prior SAC activation still induces SNM1B phosphorylation (Figure 3.1G; 3.S3D).  
Together, these data support the hypothesis that Aurora B or CDK1 inhibition may 
promote the loss of SNM1B phosphorylation via SAC bypass.   
To further examine SNM1B phosphorylation after mitotic exit, cells were blocked 
with nocodazole for 18 hours and released into drug-free media for 4 or 8 hours to allow 
for cell cycle progression.  Progression was monitored by cyclin A and B1 levels, which 
increased and decreased after release, respectively.  Phosphorylated SNM1B was no 
longer detected after mitotic release at either the 4 or 8 hour timepoint (Figure 3.4B).  
These results indicate that SNM1B is no longer phosphorylated as cells exit mitosis. 
Identification of a major phosphorylation site on SNM1B 
To identify the phosphorylation site(s) on SNM1B, deletion mutants were 
generated (Figure 3.5A).  All mutants harbored a V5 tag at the C-terminus and retained 
the TRF2 binding domain within residues 496-532.  Upon treatment with nocodazole, 
the SNM1B mutant consisting of only the catalytic N-terminal domain (N-term SNM1B-
V5) did not show a mobility shift similar to the WT protein (Figure 3.5B).  This indicates 
that SNM1B is phosphorylated on its C-terminus.  Upon examination of SNM1B mutants 
lacking various regions of the C-terminal domain, only the Δ399-465 and the Δ466-495 
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mutants lacked a discernable shift in the Western blot after treatment with nocodazole 
(Figure 3.5C).  Upon further investigation using the Phos-tag SDS-PAGE system, the 
Δ399-465 mutant revealed a more drastically shifted band compared to the Δ466-495 
mutant after exposure to nocodazole (Figure 3.5D).  This suggests that a major 
phosphorylation site resides within residues 466-495 of SNM1B.  There are only three 
highly conserved serine or threonine residues within this region of SNM1B – S474, 
S481, and S487 (Figure 3.5E).  These residues were mutated to alanines by site-
directed mutagenesis to create a triple point mutant (3SA SNM1B).  When cells 
expressing this mutant form of SNM1B were treated with nocodazole, there was no 
distinct shift observed in the Western blot, suggesting that SNM1B is phosphorylated at 
one or several of these sites during mitosis (Figure 3.5F).  The S474A and S481A 
individual point mutants were generated, and only the S481A mutant showed decreased 
phosphorylation after nocodazole treatment (Figure 3.5G).  These findings reveal that 
S481 is a major phosphorylation site on SNM1B. 
SNM1B phosphorylation is dispensable for its localization to stalled forks and for its 
interaction with TRF2 
 To ensure that the point mutations do not potentially disrupt known functions of 
SNM1B in response to replication stress, cellular localization was examined by 
fractionations and foci formation.  Previous studies demonstrate that SNM1B forms 
subnuclear foci in response to the polymerase inhibitor, aphidicolin, and data from 
Chapter 2 shows that SNM1B becomes highly associated with chromatin after 
aphidicolin treatment 5.   Both WT and 3SA SNM1B displayed an increase in chromatin 
association after exposure to aphidicolin, revealing that the mutations in SNM1B do not 
alter the localization of the protein in response to replication stress (Figure 3.6A).  This 
is supported by the finding that, similar to WT SNM1B, the 3SA mutant exhibits 
increased foci formation after aphidicolin-induced fork stalling compared to the 
untreated controls (Figure 3.6B) 5.  This increase was approximately 4-fold and 2.3-fold 
for the WT and 3SA mutant, respectively.  The percentage of cells with foci formation 
was slightly higher in all conditions for 3SA SNM1B compared to WT, but this finding 
needs to be further investigated.   
 
84 
Phosphorylation can often serve as a key regulator of protein interactions during 
cellular processes.  Phosphorylation can both initiate new protein complex formation 
and cause dissociation of existing binding partners.  One major binding partner of 
SNM1B is the telomere protein, TRF2.  SNM1B has been shown to interact with TRF2 
for the protection of telomere ends during DNA replication in S-phase 46.  It is unknown 
whether or not SNM1B and TRF2 maintain their association during mitosis, or if their 
interaction is affected by protein modifications.  To examine this, SNM1B was 
immunoprecipitated from nocodazole-treated cells expressing Myc-TRF2.  Myc-TRF2 
co-immunoprecipitated with N-term SNM1B in both asynchronous and nocodazole-
treated cells (Figure 3.6C).  The same result was observed when the 3SA SNM1B 
mutant was immunoprecipitated (Figure 3.6D).  These data suggest that the 
phosphorylation of SNM1B does not affect the interaction between TRF2 and SNM1B 
during mitosis. 
S481A SNM1B mutant is polyubiquitinated during mitosis 
Several DNA repair proteins have been previously shown to undergo 
proteasomal degradation after phosphorylation in mitosis.  FANCM, a member of the FA 
pathway, becomes hyperphosphorylated and subsequently degraded during mitosis to 
allow for the release of the FA core complex from chromatin 47.  Additionally, the BLM 
helicase contains a phospho-degron recognized by the E3 ubiquitin ligase, Fbw7𝛼, that 
polyubiquitinates and targets BLM for degradation 17.  Based on the findings that 
phosphorylated SNM1B is reduced as cells exit mitosis, I hypothesized that 
phosphorylated SNM1B may be similarly targeted for degradation by the proteasome.  
To examine this, HCT116 cells were transiently transfected with plasmids expressing 
WT or S481A SNM1B-V5, treated with nocodazole and MG132, and harvested for 
immunoprecipitation of K48-linked ubiquitin.  After MG132 treatment, a distinct smearing 
pattern representing polyubiquitination was observed for the S481A mutant that was not 
observed for the WT control (Figure 3.7).  This demonstrates that phosphorylation on 
S481 may be important for preventing polyubiquitination and subsequent degradation of 
SNM1B in mitosis. 
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Discussion 
This study has revealed a novel modification of SNM1B during mitosis, a phase 
of the cell cycle in which little is known about the functions of SNM1B.  I have shown 
that SNM1B is predominantly phosphorylated in G2/M-phases and that phosphorylated 
SNM1B is drastically reduced as cells exit mitosis.  The PIKK members, ATM, ATR, and 
DNA-PKcs, which function in DNA repair pathways, are not involved in the 
phosphorylation of SNM1B.  Additionally, inhibition of mitotic kinases during SAC 
activation revealed that PLK1 and NEK2 do not alter the phosphorylation status of 
SNM1B.  However, inhibition of Aurora A, Aurora B, and CDK1 resulted in a reduction of 
phosphorylation, which is most likely due to SAC bypass.  This finding is supported by 
evidence that SNM1B phosphorylation is reduced as cells are released from mitotic 
arrest in the absence of mitotic kinase inhibitors.  I have also identified that S481 is a 
major site of phosphorylation on SNM1B, and that mutation of this serine to an alanine 
does not disrupt SNM1B localization during replication stress or its interaction with the 
telomere protein, TRF2.  However, the S481A mutation does promote polyubiquitination 
of SNM1B, suggesting that phosphorylation may play a role in regulating SNM1B 
stability.   
SNM1B has been previously shown to function in the prophase checkpoint during 
mitosis.  Upon exposure to microtubule inhibitors, SNM1B-deficient cells exhibit 
increased levels of phospho-histone H3 and a failure to arrest in prophase with 
uncondensed chromatin 19.  Similar phenotypes were observed for the metallo-β-
lactamase/βCASP family member, SNM1A, and for the ubiquitin ligase, CHFR, both of 
which have been implicated in the early mitotic checkpoint 21,22.  Knockdown of SNM1A 
and CHFR also sensitizes cells to microtubule inhibitors, such as nocodazole 21,23.  This 
observation prompted us to examine the potential role of SNM1B in cellular survival 
after spindle stress.   
Cells that experience prolonged mitotic arrest upon microtubule inhibition (MTI) 
can succumb to one of several fates.  They can resume normal cell division, undergo 
apoptosis soon after mitosis, or fail cytokinesis and enter the tetraploid state.  These 
tetraploid cells can continue dividing, become senescent, or execute cell death at a later 
point in time 48–50.  These fates differ depending on the cell type and the MTI used to 
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induce arrest.  In response to nocodazole-induced arrest, most HCT116 cells are able 
to eventually exit mitosis, with a small proportion of cells undergoing apoptosis in the 
following interphase 51.  Since SNM1B-depleted HCT116 cells exhibit increased 
sensitivity to nocodazole treatment in a long-term colony formation assay, it is possible 
that knockdown cells apoptose in the following interphase or in a tetraploid state after 
release from microtubule inhibition.  This is supported by findings that SNM1B-deficient 
cells display binucleation and proliferation defects through apoptosis, even in the 
absence of spindle stress 52–55.   
Interestingly, prolonged mitotic arrest induces telomere uncapping, increased 
telomere dysfunction-induced foci (TIF), and loss of telomeric 3’ overhangs 56.  
Telomeres are normally protected by the shelterin complex and the formation of a T-
loop structure, which involves insertion of the 3’ overhang back into the double-stranded 
portion of the DNA 57,58.  Knockdown of the shelterin protein, TRF2, has been shown to 
exacerbate telomere deprotection and increase mitotic cell death 59.  Since SNM1B 
physically interacts with TRF2 and has been implicated in the generation of 3’ 
overhangs at leading-strand telomeres, SNM1B depletion could also promote telomere 
deprotection.  If so, this may provide an explanation as to why knockdown of SNM1B 
sensitizes cells to nocodazole.  To determine if this phenotype is associated with 
telomere uncapping, TIF formation could be analyzed after SNM1B knockdown and 
mitotic arrest.  It would also be interesting to examine the sensitivity of other cell lines to 
nocodazole and to additional types of microtubule inhibitors.    
The phosphorylation of SNM1B that we observed in this study was most 
prominent during G2-phase and mitosis, suggesting that mitotic kinases may contribute 
to this modification.  Interestingly, inhibition of Aurora B and CDK1 both reduced 
SNM1B phosphorylation, but only after prior SAC activation induced by nocodazole.  
Therefore, we hypothesize that this loss of SNM1B phosphorylation could be due to 
SAC bypass, as studies have shown that Aurora B and CDK1 inhibition during MTI-
induced mitotic arrest leads to bypass of this checkpoint 25,42,44.  After nocodazole 
treatment, CDK1-inhibited cells can rapidly exit mitosis, whereas cells exposed to 
Aurora B inhibitors stay arrested for a longer period of time 25,42–44,60.  This supports the 
finding that SNM1B phosphorylation is completely lost in nocodazole and CDK1i-treated 
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cells, compared to AurBi-treated cells where some SNM1B phosphorylation is retained.   
Although Aurora B and CDK1 inhibition can lead to SAC bypass, these effects can be 
suppressed by co-treatment with the proteasome inhibitor, MG132 43,44.  It is well 
established that APC-mediated degradation of cyclin B serves as a key regulator of 
mitotic exit, and by preventing this degradation process with the addition of MG132, 
cells will remain stalled in metaphase 45,61.  Based on the findings in this current study, 
co-treatment of AurBi or CDK1i with MG132 results in retention of phosphorylated 
SNM1B.  This suggests that MG132 may be suppressing SAC bypass, therefore 
preventing the loss of SNM1B phosphorylation that is normally observed in AurBi- or 
CDK1i-treated cells.  This concurs with data showing that SNM1B phosphorylation is 
reduced as cells are released from nocodazole arrest in the absence of kinase 
inhibitors.  The loss of SNM1B phosphorylation coincides with increased levels of 
phosphatase activity upon mitotic exit, therefore the role of protein phosphatases in the 
potential dephosphorylation of SNM1B should be examined as well.  
 SAC bypass has also been observed in response to Aurora A inhibition in MTI-
arrested cells 62,63.  Treatment with lower concentrations of the Aurora A inhibitor, 
MLN8237, produced no change in SNM1B phosphorylation.  However, at a higher 
concentration of 1µM, SNM1B phosphorylation was reduced to similar levels as 
observed for Aurora B inhibition.  It has been previously reported that MLN8237 
concentrations higher than 50nM could also potentially inhibit Aurora B 41. This suggests 
that treatment with MLN8237 at higher doses could promote SAC bypass, either 
through inhibition of Aurora A and/or Aurora B.  Nonetheless, my findings indicate that 
mitotic kinases regulate the phosphorylated state of SNM1B, either directly or indirectly.   
 It would be interesting to determine whether other kinases contribute to SNM1B 
phosphorylation.  The identification of S481 as a major SNM1B phosphorylation site 
could guide future studies to determine the kinase involved in this PTM.  The S481 
residue resides in a common pSP or pSP-like motif that is recognized by several 
families of kinases, including ERK/MAPK and other CDKs 64.  Using kinase prediction 
software, JNK, p38 MAPK, and CDK5 have been identified as the top potential kinases 
acting on S481 in SNM1B 65.  Studies have shown that p38 MAPK and JNK, kinases 
generally involved in stress response pathways, are activated in mitosis in response to 
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microtubule inhibition 66–68.  CDK5 is a member of the CDK family and has been mainly 
associated with regulating the cytoarchitecture of the central nervous system 69.  
However, it has also been implicated in the regulation of actin dynamics and 
microtubule stability 69.  Since the MAPK and CDK5 kinases have been reported to be 
active in mitosis or function in processes that are required for spindle formation, they 
may have a yet unknown role in SNM1B phosphorylation.  These kinases, and 
potentially others, should be tested for their effect on the modification of SNM1B.
 Although SNM1B phosphorylation is dispensable for its known interaction with 
TRF2, it is possible that this PTM can alter other protein interactions involving SNM1B.  
For example, SNM1B has been reported to interact with PSF2, a member of the GINS 
complex that is important for initiation of DNA replication 70.  SNM1B may interact with 
PSF2 during replication in S-phase, and phosphorylation could allow it to disassociate 
from PSF2 as cells enter mitosis.  However, the role of phosphorylation and the 
dynamics of this interaction is still unknown and requires further investigation.  SNM1B 
has also been reported to interact with proteins that function in spindle assembly during 
mitosis, specifically β-tubulin and astrin 19,71.  Mass spectrometry experiments revealed 
an association between SNM1B and β-tubulin, which is a major component of 
cytoskeletal microtubules and mitotic spindles 71.  However, the functional importance of 
this interaction has yet to be elucidated.  Astrin is a mitotic spindle-associated protein 
that is essential for progression through mitosis, and knockdown of astrin results in 
multipolar or disordered spindles and cell death 72.  The interaction between SNM1B 
and astrin is enhanced after mitotic arrest by nocodazole, and both proteins have been 
shown to localize to the centrosome 19.  Therefore, we cannot rule out the possibility 
that SNM1B phosphorylation affects this interaction with astrin or alters its localization to 
centrosomes during mitosis.   
Several DNA repair proteins undergo proteasomal degradation after 
phosphorylation in mitosis.  For example, FANCM and BLM are both phosphorylated to 
target them for subsequent polyubiquitination, which in turn regulates various repair 
processes within the cell 41,77.  Based on the findings that phosphorylated SNM1B is 
reduced as cells exit mitosis, I hypothesized that phosphorylated SNM1B may be 
degraded by the proteasome.  Unexpectedly, the S481A SNM1B mutant, which disrupts 
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phosphorylation of SNM1B during mitosis, exhibited increased polyubiquitination 
compared to the WT control.  This suggests that the loss of phosphorylation promotes 
polyubiquitination and subsequent degradation of SNM1B rather than preventing it.  
SNM1B has previously been shown to be polyubiquitinated, and this polyubiquitination 
can be prevented by binding to TRF2 73.  I have shown that non-phosphorylatable 
SNM1B mutants can still interact with TRF2, indicating that polyubiquitination of the 
S481A mutant is not induced by disruption of TRF2 binding.  However, it is possible that 
phosphorylation facilitates an unknown interaction with another protein that regulates 
the stability of SNM1B.  Loss of this phosphorylation, and therefore loss of the 
stabilizing interaction, could then lead to proteasomal degradation.   
Overall, results from this study reveal an important role for SNM1B in mitosis and 
provide insight into the regulation of SNM1B by post-translational modifications.  
Because SNM1B functions during various processes within the DDR, elucidating the 
mechanisms that control its functions will help us understand how it prevents genomic 
instability. 
Materials and Methods 
Generation of Cell Lines and SNM1B Mutants 
SNM1B deletion constructs and point mutants were generated using Q5 site-
directed mutagenesis (NEB) according to the manufacturer’s instructions.  A previously 
described pLL-IRES-GFP lentiviral vector harboring siRNA-resistant SNM1B cDNA was 
used as the template for mutagenesis 4.  This SNM1B cDNA contains a C-terminal V5 
epitope tag, and an empty vector (EV) was used as a control.  Lentiviruses were 
generated by co-transfecting the lentiviral constructs with packaging plasmids pLP1, 
pLP2, and pVSVG (Invitrogen) into 293T cells using calcium phosphate.  The viral 
supernatants were collected after 48 hours and filtered through 0.45mm PVDF filters 
(Millipore).  HCT116 and U2OS cells were transduced with 1 ml viral media containing 
4μg/ml polybrene and 1 ml culture media supplemented with 10% FBS for 24 hours.  
Cells were harvested 24 hours later, and expression of the SNM1B-IRES-GFP cassette 
was determined by flow cytometry.  GFP-positive HCT116 cells were sorted (UM Flow 
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Cytometry Core) to increase the percentage of cells expressing SNM1B within the 
population. 
Nocodazole Sensitivity Assay 
HCT116 EV cells were transfected with 50nM NS or siSNM1B siRNAs using 
Lipofectamine 2000 (Invitrogen) and treated with 60ng/ml nocodazole at 48 hours post-
transfection.  After 24 hours in nocodazole, cells were harvested by mitotic shake-off, 
thoroughly washed in PBS, and plated at low density in 12-well plates in triplicate.  Cells 
were grown for 6-9 days and fixed with 10% methanol/10% acetic acid for 10 min at 
room temperature.  Cells were stained with 1% crystal violet in methanol for 10 min, 
washed thoroughly, and air-dried overnight.  Crystal violet was resolubilized using 0.1% 
SDS in methanol and absorbance was measured at 595nm.  Percent survival was 
calculated relative to DMSO-treated controls and plotted as the mean and SEM from 
three independent experiments.     
Cell Synchronization and Cell Cycle Analyses 
 For the double thymidine block, HCT116 cells stably expressing WT SNM1B-V5 
were treated with 2mM thymidine for 18 hours, released into fresh media for 6 hours, 
and exposed to 2mM thymidine for another 18 hours.  After washing with PBS, cells 
were released from the block and harvested at 0, 2, 4, 6, and 8 hours for cell cycle 
analysis and immunoblotting.  For synchronization in G2-phase or mitosis, cells were 
treated with 9μM RO3306 (CDK1i; Cayman Chemical) for 20 hours or 400ng/ml 
nocodazole for 18 hours, respectively.  For nocodazole release experiments, a final 
concentration of 100ng/ml was used.  All mitotic cells were harvested by mitotic shake-
off. 
 To examine cell cycle profiles after synchronization, cells were fixed with cold 
70% ethanol, stored at -20°C, and stained with a solution containing 50μg/ml propidium 
iodide, 50μg/ml RNase A, and 0.1% Triton X-100 for 30 minutes at room temperature.  
Cells were analyzed using an Accuri C6 or Novocyte flow cytometer and FlowJo 
software. 
 
91 
Protein Kinase Inhibition 
 Protein kinase inhibitors were used as follows: ATM, KU-55933 (10μM, Cayman 
Chemical); ATR, VE-822 (1μM, Cayman Chemical); DNA-PKcs, NU7026 (20μM, Tocris 
Biosciences); Aurora A, MLN8237 (20nM, 100nM, 1μM, Cayman Chemical); Aurora B, 
ZM447439 (5μM, Tocris Biosciences); PLK1, BI-6727 (25nM, 1μM, Cayman Chemical); 
NEK2, INH6 (50μM, Cayman Chemical); CDK1, RO3306 (9μM, Cayman Chemical). 
Transient Transfections 
 HCT116 or 293T cells were plated in 6-well plates and transfected with 2.5μg WT 
or mutant SNM1B-V5 lentiviral vector using Lipofectamine 2000 as instructed by the 
manufacturer.  At 24 hours post-transfection, cells were treated with 400ng/ml 
nocodazole and harvested 18 hours later by mitotic shake-off.  For ubiquitin co-
immunoprecipitation experiments, HCT116 cells were plated in 10cm dishes and 
transfected with 10μg WT or mutant SNM1B-V5 pEF6 vector using Lipofectamine 2000.  
At 24 hours post-transfection, cells were treated with 400ng/ml nocodazole for 18 hours, 
treated with or without 40μM MG132 (Sigma) for 1 hr, and harvested by mitotic shake-
off.  For TRF2 co-immunoprecipitations, HCT116 cells were co-transfected with 5μg WT 
or mutant SNM1B-V5 lentiviral vector and 5μg of a construct expressing Myc-TRF2 
using Lipofectamine 2000.  At 24 hours post-transfection, cells were treated with 
400ng/ml nocodazole for 18 hours and harvested by mitotic shake-off.  
Western Blot Analyses 
Cells were harvested and lysed on ice for 1 hour in CSK buffer (10mM PIPES pH 
6.8, 100mM NaCl, 300mM sucrose, 1mM MgCl2, 0.1% Triton X-100) containing 
protease inhibitors (Roche Complete Mini EDTA-free), phosphatase inhibitors (Roche 
PhosSTOP), and benzonase (Sigma).  Lysates were centrifuged at 14,000 RPM for 20 
min and protein concentrations were determined using the Bradford assay (BioRad).  
Cell extracts were resolved by SDS-PAGE and transferred following standard 
procedures.  For Phos-tag SDS-PAGE, 25-50μM phos-binding reagent acrylamide 
(APExBIO) and 10mM ZnCl2 were added to bis-tris-HCl resolving gels before 
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polymerization.  Separation and transfer were performed as previously described 74.  
Proteins were analyzed using the appropriate primary and secondary antibodies, and 
bands were visualized using Li-Cor Odyssey 2.1 software or the SuperSignal West Pico 
system (Pierce).  ImageJ was used for Western blot protein quantifications. 
The following primary antibodies were used:  V5 (Invitrogen); BLM (Novus 
Biologicals); Cyclin B1 (Santa Cruz); Cyclin A (Santa Cruz); phospho-histone H3 S10 
(Cell Signaling); phospho-KAP1 S824 (Bethyl); phospho-CHK1 S345 (Cell Signaling); 
H2AX (Millipore); Myc-tag (Cell Signaling); Vinculin (Cell Signaling); GAPDH (Cell 
Signaling and Santa Cruz).  Secondary antibodies were: IRDye conjugated goat anti-
rabbit or anti-mouse IgG (Li-Cor Biosciences) and HRP-conjugated anti-mouse IgG 
(Jackson ImmunoResearch).  
Lambda Phosphatase Treatment 
HCT116 cells stably expressing WT SNM1B-V5 were treated with DMSO or 
400ng/ml nocodazole for 18 hours.  Cells were lysed as described above without the 
addition of phosphatase inhibitors.  Extracts were treated with lambda protein 
phosphatase (NEB) according to the manufacturer’s instructions and incubated at 30°C 
for 20 min.  Controls were incubated on ice with an equivalent amount of buffer without 
lambda phosphatase and phosphatase inhibitors were added to one sample to inhibit 
enzymatic activity.  BLM phosphorylation was analyzed as a control.  
Hoechst Staining and Cell Sorting 
HCT116 cells stably expressing WT SNM1B-V5 were suspended at 1.5 x 106 
cells/ml in McCoy’s medium containing 2% FBS.  Cells were incubated with Hoechst 
dye at a final concentration of 5μg/ml for 30 min at 37°C with intermittent shaking.  
Fluorescence-activated cell sorting (FACS) was performed to sort the cells into G1-, S-, 
and G2/M-phase populations based on DNA content.  Cells were lysed, and 
immunoblotting was used to assess WT SNM1B-V5 protein levels in each phase of the 
cell cycle.    
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Cellular Fractionations 
HCT116 cells stably expressing WT or 3SA SNM1B-V5 were treated with DMSO 
or 1μM aphidicolin for 24 hours.  Cells were harvested and pellets were first 
resuspended in fractionation buffer I (50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA, 
0.2% NP-40, supplemented with protease and phosphatase inhibitors) for 5 min on ice.  
After centrifugation at 1000 × g for 5 min, the supernatant was collected (cytoplasmic 
fraction), and the pellets were washed with fractionation buffer I.  The nuclear pellets 
were then lysed for 40 min on ice with fractionation buffer II (50mM HEPES pH 7.5, 
150mM NaCl, 1mM EDTA, 0.5% NP-40, supplemented with protease and phosphatase 
inhibitors).  The supernatants were collected (nuclear faction) after centrifugation at 
16,000 × g for 15 min. The final pellets were lysed in RIPA buffer (50mM Tris-HCl pH 
8.0, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, supplemented 
with protease and phosphatase inhibitors), sonicated, and cleared by centrifugation at 
16,000 × g for 20 min (chromatin fraction).  The whole cell extracts (WCEs) were 
prepared in a similar manner as the chromatin fractions.  Equal concentrations of each 
fraction were analyzed by immunoblotting, with GAPDH and H2AX serving as controls 
for cytoplasmic and chromatin fractions, respectively. 
Immunofluorescence of Subnuclear Foci 
HCT116 cells stably expressing WT or 3SA SNM1B-V5 were grown on glass 
coverslips in 12-well plates and treated with DMSO or 1μM aphidicolin for 24 hours.  
Cells were fixed in ice-cold 70% methanol/30% acetone for 20 min at -20°C and air-
dried at room temperature.  Cells were stained with primary anti-V5 antibody 
(Invitrogen) for 45 min followed by anti-mouse Alexa Fluor 488 secondary antibody 
(Invitrogen Molecular Probes) for 45 min.  Coverslips were mounted on slides using 
ProLong Gold Antifade Reagent with DAPI (Life Technologies) and images were 
acquired using an Olympus BX61 microscope and FISHview software (Applied Spectral 
Imaging). 
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Co-Immunoprecipitations 
Cells were lysed for 1 hour at 4°C with rotation in CSK buffer (10mM PIPES pH 
6.8, 100mM NaCl, 300mM sucrose, 1mM MgCl2, 0.1% Triton X-100) containing 
protease inhibitors (Roche Complete Mini EDTA-free), phosphatase inhibitors (Roche 
PhosSTOP), and benzonase (Sigma).  Lysates were centrifuged at 14,000 RPM for 20 
min and protein concentrations were determined using the Bradford assay (BioRad).  
Lysates (1-2mg) were pre-cleared for 30 min with washed Protein G Sepharose (GE 
Healthcare) or Protein A Agarose (Roche) beads and incubated with anti-V5 antibody 
(Invitrogen) or anti-Ubiquitin K48-specific antibody (Millipore) for 15 min at 4°C with 
rotation.  Beads were added to the samples and rotated for an additional 2 hours.  
Samples were washed 3 times with CSK buffer and proteins were eluted from the beads 
with Laemmli buffer (BioRad) by heating at 95°C for 5 min. 
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Figure 3.1 SNM1B is phosphorylated during G2-phase and mitosis  
(A) EV HCT116 cells transfected with NS or siSNM1B siRNAs were treated with 
60ng/ml nocodazole for 24 hrs.  Mitotic shake-off cells were plated at low density and 
allowed to proliferate for 6-9 days.  Percent survival was determined relative to a 
DMSO-treated control.  Data represent the mean ± SEM of three independent 
experiments. **p<0.01 (B) WT SNM1B HCT116 cells were treated with 400ng/ml 
nocodazole for 18 hrs and harvested by mitotic shake-off.  Cells were lysed and 
proteins were analyzed by Western blot. (C) WT SNM1B HCT116 cells were 
synchronized as in (B) and lysates were treated with or without lambda phosphatase 
(lPPase).  Phosphorylation status of SNM1B-V5 was examined via Western blot.  
(D) WT SNM1B HCT116 cells were incubated with 5μg/ml Hoechst dye for 30 min and 
sorted using FACS.  Sorted cells were lysed for Western blot analysis. (E and F) WT 
SNM1B HCT116 cells were released from a double thymidine block for the indicated 
amounts of time and collected for propidium iodide staining and Western blot analysis.  
The ratio of modified/unmodified SNM1B-V5 protein was calculated and plotted along 
with the percentage of cells in G2/M-phase. (G) WT SNM1B HCT116 cells were treated 
with 9μM RO3306 (CDK1i) for 20 hrs and harvested for Western blot analysis. The 
arrowhead labels the shifted, phosphorylated form of SNM1B.  AS, Asynchronous 
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Figure 3.2 Dependence of SNM1B phosphorylation on PIKK and mitotic kinases  
(A) Experimental timeline for kinase inhibitor experiments in panels B, D, and E. WT 
SNM1B HCT116 cells were treated with 400ng/ml nocodazole for 18 hrs followed by the 
addition of each kinase inhibitor for 1 hr. (B) Western blot analysis of cells treated with 
PIKK inhibitors. ATMi, ATM (10μM); PKi, DNA-PKcs (20μM); ATRi, ATR (1μM)            
(C) HCT116 cells were transfected with plasmids expressing WT and mutant SNM1B-
V5 and treated with 400ng/ml nocodazole for 18 hrs.  Phosphorylation status was 
examined via immunoblotting. (D) Western blot analysis of cells treated with the Aurora 
B inhibitor, AurBi.  pH3 S10 was used as a control to validate kinase inhibition.            
(E) Western blot analysis of cells treated with mitotic inhibitors. AurAi, Aurora A (1μM); 
AurBi, Aurora B (5μM); PLK1i, PLK1 (1μM); NEK2i, NEK2 (50μM); CDK1i, CDK1(9μM). 
The arrowhead labels the shifted, phosphorylated form of SNM1B. AS, Asynchronous  
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Figure 3.3 Evaluation of SNM1B phosphorylation on Aurora consensus sites 
(A) Protein sequence alignments for Aurora consensus sites within SNM1B.  The 
predicted serine or threonine for phosphorylation is boxed. (B) HCT116 cells were 
transfected with vectors expressing WT or mutant SNM1B-V5 and treated with 
400ng/ml nocodazole for 18 hrs.  Cells were lysed and protein extracts were resolved 
using Phos-tag SDS-PAGE. (C) HCT116 cells were treated as in (B) and protein lysates 
were resolved using standard SDS-PAGE. The arrowhead labels the shifted, 
phosphorylated form of SNM1B.  Neg, Negative control 
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Figure 3.4 SNM1B phosphorylation decreases as cells progress out of mitosis 
(A) WT SNM1B HCT116 cells were treated with 400ng/ml nocodazole for 18 hrs and 
the Aurora B kinase inhibitor (AurBi-5μM) was added in the presence or absence of 
40μM MG132 for the final hour.  Cells were harvested by mitotic shake-off and protein 
lysates were resolved using Phos-tag SDS-PAGE. (B) WT SNM1B HCT116 cells were 
treated with 100ng/ml nocodazole for 18 hrs and cells were harvested at the indicated 
timepoints after release.  Cell extracts were examined via Western blot.  Cyclins A and 
B1 were used as controls for cell cycle progression.  Vinculin serves as a loading 
control for SNM1B-V5, whereas GAPDH was used as a loading control for the cyclins.  
The arrowhead labels the shifted, phosphorylated form of SNM1B. AS, Asynchronous 
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Figure 3.5 SNM1B is phosphorylated within its C-terminal domain on serine 481  
(A) Schematic of SNM1B deletion mutants. The dark grey region represents the 
MBL/βCASP domain and the light grey region depicts the V5 epitope tag. 
(B, C, D) HCT116 cells stably expressing WT or mutant SNM1B-V5 were treated with 
400ng/ml nocodazole for 18 hrs and the phosphorylation status was examined using 
standard SDS-PAGE (B and C) or Phos-tag SDS-PAGE (D) followed by Western 
blotting. (E) Protein sequence alignments illustrating the three most conserved serine 
residues (grey boxes) within the 466-495aa region of SNM1B.  These sites were 
mutated to alanines in combination to generate the 3SA SNM1B mutant.  (F) HCT116 
cells stably expressing WT or 3SA SNM1B-V5 were treated with 400ng/ml nocodazole 
for 18 hrs and protein extracts were examined via Western blot. The arrowhead labels 
the shifted, phosphorylated form of SNM1B. (G) Single point mutants were generated 
for the S474 and S481 residues and HCT116 cells were transfected with vectors 
expressing WT or mutant SNM1B-V5.  Cells were treated with 400ng/ml nocodazole 
and the phosphorylation of mutant SNM1B-V5 was examined by immunoblotting.  
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Figure 3.6 SNM1B phosphorylation is not required for its recruitment to stalled 
forks or for its interaction with TRF2  
(A) WT and 3SA SNM1B HCT116 cells were treated with 1μM aphidicolin for 24 hrs and 
harvested for cellular fractionation.  Immunoblotting was performed to assess protein 
levels within each fraction.  GAPDH and H2AX were used as controls for cytoplasmic 
and chromatin fractions, respectively. (B) WT and 3SA SNM1B HCT116 cells were 
treated with 1μM aphidicolin for 24 hrs, fixed, and stained for the visualization of 
SNM1B-V5 foci.  The percentage of cells positive for SNM1B-V5 foci was calculated 
and plotted in the bar graph.  (C and D) HCT116 cells were co-transfected with vectors 
expressing the WT, 3SA, or N-terminus of SNM1B (N-term) and Myc-TRF2.  Cells were 
treated with 400ng/ml nocodazole and harvested for co-immunoprecipitation using an 
anti-V5 antibody.  A bead-only sample was used as a control (Bead).  Aph, Aphidicolin 
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Figure 3.7 The S481A SNM1B mutant is polyubiquitinated in mitosis 
HCT116 cells were transfected with plasmids expressing WT or S481A SNM1B and 
treated with 400ng/ml nocodazole for 18 hrs with or without the addition of 40μM 
MG132 for the last hour.  Cells were harvested for co-immunoprecipitation using an 
antibody against K48-linked ubiquitin and a bead-only sample was used as a control 
(Bead).  
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Figure 3.S1 Validation of cell synchronization and SNM1B phosphorylation   
(A) Representative cell cycle profiles of WT SNM1B HCT116 cells treated with 
400ng/ml nocodazole for 18 hrs or 9μM RO3306 (CDK1i) for 20 hrs. Western blots 
showing common markers for G2- or M-phase synchronization. (B) U2OS cells stably 
expressing WT SNM1B-V5 and 293T cells transfected with a vector expressing WT 
SNM1B-V5 were treated with 400ng/ml nocodazole for 18 hrs. SNM1B phosphorylation 
was examined via Western blot. The arrowhead labels the shifted, phosphorylated form 
of SNM1B. (C) WT SNM1B HCT116 cells synchronized by a double thymidine block or 
nocodazole were analyzed using Phos-tag SDS-PAGE. AS, Asynchronous, Noc, 
Nocodazole, Thym, Thymidine Block 
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Figure 3.S2 Controls for protein kinase inhibition    
(A) WT SNM1B HCT116 cells were pre-treated with ATM or DNA-PKcs kinase inhibitors 
for 1 hr and treated with 10μg/ml bleomycin for 30 min.  Cells were harvested for pKAP1 
analysis via Western blot. (B) WT SNM1B HCT116 cells were pre-treated with an ATR 
kinase inhibitor for 1 hr and exposed to 15 J/m2 UV.  Cells were allowed to recover for 
30 minutes and then harvested for pCHK1 analysis via Western blot. (C) WT SNM1B 
HCT116 cells were treated with nocodazole for 18 hrs followed by treatment with mitotic 
kinase inhibitors for an additional 1 hr. SNM1B phosphorylation was examined by 
immunoblotting.  The arrowhead labels the shifted, phosphorylated form of SNM1B.   
Ai, Aurora A (20nM, 100nM); AurBi, Aurora B (5μM); PLK1i, PLK1 (25nM); CDK1i, 
CDK1(9μM). The arrowhead labels the shifted, phosphorylated form of SNM1B. Unt, 
Untreated; AS, Asynchronous 
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Figure 3.S3 Cell cycle analysis and SNM1B phosphorylation status in mitotic cells 
treated with Aurora B or CDK1 inhibitors 
(A) WT SNM1B HCT116 cells were synchronized with 400ng/ml nocodazole and 5μM 
Aurora B kinase inhibitor was added for 1, 3, or 6 hrs.  Cells were harvested for 
propidium iodide staining and the cell cycle profiles are shown. (B) WT SNM1B HCT116 
cells were synchronized with 400ng/ml nocodazole, after which 5μM Aurora B kinase 
inhibitor or 40μM MG132 was added alone or in combination for 1 hr.  Cells were 
harvested for propidium iodide staining and the cell cycle profiles are shown. (C) WT 
SNM1B HCT116 cells were synchronized with 400ng/ml nocodazole, after which 9μM 
RO3306 (CDK1i) or 40μM MG132 was added alone or in combination for 1 hr. Cells 
were harvested for Western blot analysis. (D) WT SNM1B HCT116 cells were treated 
with 400ng/ml nocodazole alone or in combination with 5μM Aurora B kinase inhibitor 
and harvested at the indicated timepoints.  Protein lysates were analyzed by Western 
blot. AS, Asynchronous; Noc, Nocodazole; AurBi, Aurora B inhibitor; CDK1i, CDK1 
inhibitor; MG, MG132   
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Chapter 4 
Discussion
 
Complete replication of the genome and accurate chromosomal segregation are 
essential for the transmission of genetic information to daughter cells.  However, during 
DNA synthesis, the replication machinery can encounter a number of obstacles that 
impede its progression and cause the fork to stall 1.  If stalled forks are not properly 
restarted, they can collapse, resulting in the formation of DNA double-strand breaks 
(DSBs).  These breaks, when mis-repaired, can lead to increased genome instability in 
the form of chromosomal gaps, breaks, deletions, amplifications, and rearrangements 
2,3.  Genome instability can also occur if the replicated DNA is aberrantly segregated 
during mitosis.  Therefore, the cell has evolved intricate mechanisms to ensure accurate 
cell division and efficient resolution of stalled replication forks.  Understanding the 
details of these molecular pathways is critical for addressing the association between 
genomic integrity and disease.  
The resolution of stalled replication forks requires the nucleolytic processing of 
DNA intermediate structures.  One DNA nuclease that has been implicated in these 
processing events is SNM1B 4.  SNM1B has known functions in DNA interstrand 
crosslink (ICL) repair and is important for the recruitment of key DNA repair proteins to 
stalled replication forks 5,6.  Herein, we have expanded on the current knowledge of the 
role of SNM1B in the resolution of replication stress and highlight potential mechanisms 
for its regulation.  We found that SNM1B is required for normal replication fork 
progression and that it participates in the late-stage processing events of 
recombination-mediated collapsed fork repair.  We also discovered that SNM1B is 
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phosphorylated during G2-phase and mitosis and that this modification may promote 
SNM1B protein stability.  In this chapter, I will discuss the implications of these findings 
and propose future directions to better understand the role of SNM1B and its regulation 
in DNA repair processes. 
Several DNA repair factors have been implicated in the resolution of stalled 
replication forks, but the coordinated actions of these proteins in this process are not 
well understood.  To elucidate the order of events that may occur at sites of replication 
stress, we examined foci formation of various DNA repair proteins relative to one 
another over time.  We found that RPA and MRE11 are recruited early to aphidicolin-
stalled forks, followed by SNM1B and FANCD2.  These data support previous findings 
that SNM1B is not required for the proper localization of RPA and MRE11 to stalled 
forks, but that it is necessary for the efficient localization of FANCD2 6.  This is also 
consistent with the discovery that SNM1B is dispensable for the early ATR-dependent 
signaling events in response to aphidicolin 6.  Since MRE11 localizes to stalled forks 
prior to SNM1B, we asked whether it may be important for recruiting SNM1B to sites of 
replication stress.  We found that the exonuclease activity of MRE11 is not necessary 
for the association of SNM1B with chromatin after exposure to aphidicolin.  This is in 
contrast to the repair factors FANCD2, CtIP, and BRCA1, which all require the 
nucleolytic function of MRE11 for their efficient localization to chromatin after fork 
stalling 7.  MRE11 has also been described to regulate foci formation and stability of 
FANCD2 8.  Seeing as FANCD2 preferentially binds to ssDNA substrates, these studies 
proposed that MRE11 processes DNA intermediates to generate ssDNA for FANCD2 
localization 8.  It is possible that SNM1B may be independently recruited to stalled forks 
to process the opposing nascent DNA strand to recruit factors such as FANCD2 and 
BRCA1.  SNM1B has been reported to bind to both MRE11 and FANCD2, so these 
factors may also rely on physical interactions to localize to stalled forks 9.  Future 
studies could expand on the functional importance of these interactions during the 
resolution of replication stress. 
 The generation of ssDNA is a common phenomenon observed at stalled forks 
induced by various forms of genotoxic stress, either through polymerase-helicase 
uncoupling or through processing of DNA intermediate structures 10.  DNA nucleases 
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play a crucial role in these processing events, but unregulated nucleolytic activity can 
lead to excessive DNA degradation and genome instability.  MRE11 is one of the 
nucleases associated with this excessive end resection, but other enzymes such as 
EXO1 and FAN1, have also been linked to uncontrolled DNA processing at stalled forks 
11–15.  This excessive degradation is prevented by members of the FA/BRCA network, 
specifically BRCA1, BRCA2, RAD51, and FANCD2 11–13,16.  Since SNM1B is important 
for the efficient localization of BRCA1 and FANCD2 to stalled forks, we examined the 
impact of SNM1B on ssDNA formation 6.  We found that SNM1B suppresses the 
formation of ssDNA in both untreated and aphidicolin-treated cells.  This suggests that 
SNM1B may recruit proteins of the FA/BRCA network to stalled forks in order to 
stabilize and protect them from excessive degradation by other nucleases, such as 
MRE11 (Figure 4.1).  Additional experiments utilizing the established DNA combing 
assay could be performed to assess whether the ssDNA in SNM1B-depleted cells is 
indeed a result of nascent DNA hyper-resection.  
 Nucleolytic digestion of annealed DNA strands at a regressed fork is one 
potential mechanism to initiate fork restart 17,18.  However, excessive degradation and 
the formation of ssDNA regions could make the fork more susceptible to breakage.  We 
demonstrated that SNM1B is important for preventing the accumulation of DSBs, as 
assessed by gH2AX and 53BP1 colocalization, which are both key regulators of the 
DSB response.  Although gH2AX is present at stalled forks prior to break formation, its 
increased colocalization with 53BP1 in SNM1B-deficient cells suggests that forks have 
begun to collapse 19.  Once a fork collapses, the DSB is resected to promote RAD51 
filament formation and homologous recombination (HR).  Our studies determined that 
SNM1B is required for efficient RAD51 foci formation following aphidicolin-induced 
replication stress.  This finding implicates SNM1B in the later stages of fork repair, 
potentially after fork collapse, to promote RAD51 loading and HR.  Similar to its role in 
the resection of leading-strand telomeres, the 5’ to 3’ nuclease activity of SNM1B could 
contribute to the generation of 3’ overhangs at DSBs after fork collapse (Figure 4.1).  
This would allow for the proper assembly of HR proteins and facilitate strand invasion of 
the homologous template.     
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Several lines of evidence have implicated SNM1B in the efficient repair of DSBs.  
Previous studies have shown that SNM1B rapidly localizes to sites of IR-induced 
damage and is involved in homology-directed repair of I-SceI-induced breaks 5,20.  To 
gain insight into the role of SNM1B in the response to replication-associated DSBs, we 
analyzed recombination products in SNM1B-deficient cells after site-specific fork 
stalling.  We revealed that SNM1B promotes HR-mediated repair after fork collapse and 
that it is specifically involved in regulating conservative short-tract gene conversion 
(STGC), which is the primary HR product generated from processing bidirectionally 
stalled forks.  Similar results have been reported for the Fanconi anemia (FA) and HR 
proteins BRCA1, BRCA2, CtIP, RAD51, FANCM, FANCA, FANCD2, and FANCP/SLX4 
21,22.  However, only some of these factors, such as BRCA1, BRCA2, and RAD51 have 
been implicated in suppressing error-prone long-tract gene conversion (LTGC) 21.  In 
comparison, SNM1B depletion results in a decrease in LTGC products compared to 
controls and does not significantly increase the absolute frequency of LTGC at 
collapsed forks.   
LTGC is an aberrant HR outcome which entails a replicative mechanism that 
copies several kilobases from the sister chromatid 23–25.  Therefore, LTGC could be 
caused by a termination failure of HR, potentially when the second non-invading strand 
is missing (one-ended DSB) or not properly coordinated with the invading strand 25.  
Interestingly, increased spatial separation between converging forks at a replication 
barrier impairs the coordination of DSB ends, thereby favoring LTGC 26.  Since the loss 
of SNM1B does not significantly bias HR towards LTGC, SNM1B may not be essential 
for the termination events during recombination or for the coordination of the invading 
and non-invading DNA ends.  These processes may rely more on the combinatorial 
actions of BRCA1, BRCA2, and RAD51.  It is possible that the nuclease activity of 
SNM1B is required for initiating the DNA resection of the invading strand that promotes 
HR.  This would explain the decrease observed for both STGC and LTGC products after 
SNM1B knockdown, since neither form of gene conversion could efficiently occur 
without proper initiation of recombination.  Interestingly, a detailed examination of 
stalled forks at a site-specific interstrand crosslink (ICL) revealed that one of the two 
converging forks undergoes reversal and that the nascent lagging strand is extensively 
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resected 27,28.  If a similar DNA intermediate formed in our system, SNM1B could 
facilitate the 5’ to 3’ end resection of the regressed lagging strand to generate the 
overhang for strand invasion.  Overall, the coordination of SNM1B and the 
aforementioned members of the FA/BRCA network may facilitate this fork regression, 
stabilization, and efficient processing of DNA intermediates to regulate HR-mediated 
repair. 
In addition to the replicative recombination products described above, small 
microhomology-mediated tandem duplications (TDs) have also been observed in 
BRCA1-mutant cells 22.  These rearrangements are associated with BRCA1-linked 
cancers and are often enriched at loci that disrupt tumor suppressor genes 29,30.  At site-
specific stalled forks, TDs are predicted to arise from an aberrant replication restart-
bypass mechanism or by microhomology-mediated template switching 22.  These 
processes are analogous to the mechanisms proposed for CNV formation, which 
frequently overlap with common fragile sites (CFSs) 31,32.  Since SNM1B is important for 
CFS stability, it may be involved in preventing TD formation at stalled replication forks 6.  
Because nonrecurrent CNVs and TDs both contain breakpoint microhomologies, we 
could sequence the rearrangement breakpoints in SNM1B-depleted cells after Tus-
induced fork stalling.  It would also be interesting to examine the combined effects of 
SNM1B and BRCA1 on TDs, as co-depletion of BRCA1 and other repair factors that 
promote CFS stability, such as BLM and FANCM, independently suppress TD formation 
22.  These studies would provide further insight into the mechanistic roles of SNM1B in 
replication fork repair and its impact on genome instability.   
 Most of what is currently known about SNM1B is on its functions in telomere 
maintenance and in the DNA damage response during S-phase 4.  However, the 
regulatory mechanisms of SNM1B and its nucleolytic activity have not been well 
characterized.  In this thesis, I examined the cellular regulation of SNM1B to gain a 
better understanding of how it is controlled during cell cycle-specific repair processes.  I 
have shown that SNM1B protein levels remain relatively unaltered throughout the cell 
cycle, but increase in S-phase in response to replication stress induced by aphidicolin or 
a double thymidine block.  These findings indicate that SNM1B is not cell cycle 
regulated in unperturbed conditions, but that the protein becomes stabilized after 
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replication fork stalling (Figure 4.1).  The stability of SNM1B may be partly controlled by 
protein interactions.  Previous studies have revealed that TRF2 binding increases the 
stability of SNM1B by preventing its polyubiquitination and subsequent degradation 33,34.  
Since TRF2 can rapidly localize to photo-induced DSBs in non-telomeric DNA, TRF2 
may help stabilize SNM1B in response to DNA damage and replication stress, as well 
as at telomeres 20,35.  PSF2, a member of the GINS complex that is required for DNA 
replication, may also support SNM1B stability.  PSF2 has been shown to interact with 
SNM1B, and its overexpression promotes SNM1B chromatin association 36.  
Interestingly, we observed increased SNM1B chromatin association after aphidicolin 
treatment, therefore it is possible that PSF2 facilitates SNM1B localization and 
stabilization after fork stalling.  PSF2 binds to SNM1B within the same region as TRF2, 
which suggests that PSF2 may stabilize SNM1B during DNA replication, whereas TRF2 
might be responsible for SNM1B stabilization at telomeres. 
 In addition to changes in protein stability, the regulation of DNA repair pathways 
also relies heavily on post-translational modifications (PTMs).  Besides 
polyubiquitination, no PTMs of SNM1B have been fully described or functionally studied.  
In this thesis, I have defined a novel phosphorylation event on SNM1B that occurs 
primarily during G2-phase and mitosis (Figure 4.1).  Phosphorylated SNM1B is reduced 
as cells exit mitosis, suggesting tight control of this regulatory event throughout the cell 
cycle.  I identified the specific residue (S481) that is phosphorylated on SNM1B and 
generated a non-phosphorylatable point mutant (S481A) to investigate its functional 
importance.  I found that the phosphorylation of SNM1B is dispensable for its chromatin 
association and foci formation at stalled forks and for its interaction with TRF2.  
However, SNM1B phosphorylation may be important for repair events outside of S-
phase. 
 SNM1B may extend its roles in replication repair into mitosis, and the 
phosphorylation event could be essential for these mitotic functions.  At loci that are 
difficult to replicate, such as CFSs and telomeres, the completion of DNA synthesis can 
be delayed.  Although late replication was assumed to occur during G2-phase, 
experimental evidence suggests that replication can extend into early mitosis.  These 
under-replicated regions trigger a non-canonical form of mitotic DNA synthesis called 
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MiDAS 37.  This pathway is a form of HR-based DNA repair that acts as a salvage 
mechanism to prevent lethal chromosome mis-segregation.  
 MiDAS has been described to resemble break-induced replication (BIR) in yeast, 
which entails repair of one-ended DSBs through strand invasion and conservative DNA 
synthesis 38–40.  This process is initiated by the cleavage of stalled forks by SLX4 and 
MUS81-EME1, which promotes POLD3-dependent replication.  Interestingly, MiDAS 
was shown to be independent of RAD51 filament formation and instead requires 
RAD52, suggesting that breaks may be repaired through a microhomology-mediated 
BIR mechanism 38.   
 MiDAS is reported to occur at both CFSs and telomeres, as both loci can be 
under-replicated as cells enter mitosis 41.  SNM1B functions in the generation of 3’ 
overhangs at telomeres and is important for maintaining fragile site stability, thereby 
associating SNM1B with these genomic regions 6,42–44.  We have shown that SNM1B is 
involved in DSB repair during replication stress, however the role of SNM1B in HR-
mediated repair during MiDAS is unknown.  Since SNM1B promotes RAD51 filament 
formation at collapsed forks, it would be interesting to determine if its phosphorylation is 
important for the switch from a canonical RAD51-dependent HR pathway in S- and G2-
phase to the RAD52-mediated MiDAS pathway in mitosis.  SNM1B has also been 
reported to physically interact with SLX4, MUS81, and MRE11, which are all proteins 
required for MiDAS, either at CFSs or at telomeres 9,37,45–47.  Therefore, SNM1B 
phosphorylation may alter its interactions with other proteins functioning at these sites 
or direct its localization to or from these genomic regions.  To determine whether 
SNM1B plays a role in MiDAS, EdU labeling of nascent DNA in aphidicolin-treated 
mitotic cells could be examined after SNM1B knockdown.  The colocalization of SNM1B 
and the EdU signal could also be analyzed to see if SNM1B is recruited to MiDAS loci.  
Additionally, the role of SNM1B phosphorylation in this process could be examined by 
performing similar studies with the S481A SNM1B mutant.   
 If under-replicated regions persist or if intermediate DNA structures are 
unresolved, this can lead to mitotic aberrations such as chromosome breaks, lagging 
chromatin, and anaphase bridges 48,49.  Anaphase bridges, which can be classified as 
either chromatin bridges or ultra-fine bridges (UFBs), are the result of intertwined sister 
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chromatids that fail to separate.  Unlike chromatin bridges, which are bulky structures 
that can be visualized using conventional DNA dyes, UFBs are stretched DNA linkages 
that are dechromatinized and can only be detected by the proteins bound to them 50,51.  
The two main factors that coat UFBs are BLM and the Polo-like kinase 1 interacting 
checkpoint helicase (PICH) 52,53.  There are at least three major types of UFBs that are 
classified by their anchorage points or the chromosomal loci from which they originate.  
These include UFBs that form at the centromere (C-UFBs), at common fragile sites (FS-
UFBs), or at telomeres (T-UFBs).  C-UFBs arise during mitosis in almost all unperturbed 
cells and are thought to occur from unresolved double-stranded DNA (dsDNA) 
catenanes, whereas FS-USBs and T-USBs contain a more aberrant DNA structure 
resulting from under-replicated DNA 52,54–57.  A fourth type of UFB has been more 
recently described as a consequence of unresolved recombination intermediates (HR-
UFBs) and are distinct from replication-associated UFBs 58,59.   
 All types of UFBs are associated with PICH and BLM, which are thought to 
regulate DNA tension or condensation and resolve complex DNA intermediate 
structures in HR-based repair, respectively.  The ssDNA-binding protein, RPA, also 
localizes to a subset of UFBs in a dependent but non-overlapping pattern with BLM, 
suggesting that BLM may potentially unwind structures to generate ssDNA 57,60.  
FANCD2 and FANCI are present at the anchorage points of FS-UFBs and may help to 
stabilize the bridges or recruit factors that are required for their resolution 54,57.  Loss of 
the repair factors that localize to UFBs, such as FANCD2 and BLM, leads to defects in 
chromosome segregation in the form of increased and persistent anaphase bridges, 
binucleation, and micronucleation 52,54,61. 
 Previous studies have revealed that SNM1B depletion results in increased 
aneuploidy, binucleation, and anaphase bridges 62,63.  This suggests that SNM1B is 
important for accurate mitotic segregation, potentially through functions at UFBs.  
SNM1B has roles at both telomeres and CFSs, thereby associating it with two loci that 
commonly form UFBs under conditions of replication stress.  It would be interesting to 
determine if SNM1B can be visualized along UFBs with PICH or BLM or if it localizes at 
the anchorage sites like FANCD2.  This could reveal potential roles of SNM1B in 
stabilizing or processing DNA structures at UFBs.  If SNM1B were to facilitate the 
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resolution of UFBs, its phosphorylation during mitosis may be important for this process.  
Studies have shown that a constitutively phosphorylated form of BLM localizes to 
anaphase bridges and prevents its degradation via cullin 3-mediated polyubiquitination 
64.  This stabilization of BLM suppresses bridge formation in mitotic cells 64.  SNM1B 
may be regulated in a similar manner, as the S481A mutant is polyubiquitinated during 
mitosis.  Phosphorylation might stabilize SNM1B by preventing its degradation by the 
proteasome, and this could allow it to aid in the resolution of UFBs.   
Another role that phosphorylated SNM1B may play during mitosis is in 
centrosome maintenance.  The centrosome is the primary center for microtubule 
organization and spindle assembly in animal cells.  Centrosomes duplicate once in S-
phase before they migrate to opposite poles of the cell during mitosis, where they 
orchestrate sister chromatid segregation by nucleating the spindle apparatus 65.  
Considering this is a vital function in cell division, centrosome maturation must be highly 
regulated to prevent genome instability.       
Several studies have shown that DDR proteins localize to centrosomes in various 
stages of the cell cycle to promote signaling and preserve centrosome integrity 66.  All 
three members of the PIKK family, in addition to effector kinases CHK1 and CHK2, 
have been visualized at the centrosome and are suspected to link the kinetics of 
microtubule formation to the DNA damage response 67.  BRCA1 and BRCA2 also 
localize to centrosomes and loss of these proteins lead to centrosome amplification 67–
69.  BRCA1 was specifically shown to be involved in the ubiquitination of g-tubulin, which 
is required for nucleating the polymerization of microtubules 68,70,71.  In addition, other 
members of the FA pathway localize to centrosomes or the mitotic spindle to maintain 
normal centrosome numbers and spindle assembly checkpoint (SAC) activation 72–74.  
One FA protein, FANCA, has been shown to be phosphorylated by the kinase NEK2, 
which is involved in bipolar spindle formation and centrosome separation.  Disruption of 
FANCA phosphorylation leads to supernumerary centrosomes, aberrant mitotic arrest, 
and sensitivity to nocodazole 73.  This indicates that FANCA, along with other DDR 
proteins, is important for maintaining centrosomal integrity.   
Like its FA pathway counterparts, SNM1B has been reported to localize to the 
centrosome 75.  Mass spectrometry studies and a yeast two-hybrid assay have also 
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identified the microtubule component, b-tubulin, and the centrosomal protein, Cep146, 
as putative SNM1B binding partners 36,76.  Additionally, SNM1B was shown to physically 
interact with the spindle-associated protein, astrin 75.  Astrin localizes to the centrosome 
and the spindle apparatus during mitosis, and the loss of this protein results in 
supernumerary centrosomes and the formation of multipolar spindles.  Although astrin is 
not required for SNM1B recruitment to the centrosome, the two proteins may act 
together to maintain appropriate centrosome numbers 75.  This same study revealed 
that knockdown of SNM1B results in increased phospho-histone H3 levels compared to 
controls, which is a similar phenotype to that observed for the FANCA phospho-mutant 
73,75.  Phosphorylation of this histone variant is a common marker for mitotic index.  
Therefore, it would be interesting to examine whether the S481A SNM1B mutant can 
localize to centrosomes or alter phospho-histone H3 levels.  Like FANCA, we also 
determined that SNM1B depletion leads to decreased survival in response to 
microtubule inhibition.  It is possible that the loss of SNM1B could disrupt centrosome 
integrity, and upon added microtubule stress, result in cell death.  To examine this 
further, we could assess centrosome number in SNM1B knockdown cells and in cells 
expressing the S481A mutant to see if chromosome segregation is affected.     
 SNM1B has been shown to function in an early mitotic prophase checkpoint, also 
known as the antephase checkpoint 75.  The prophase checkpoint delays commitment to 
mitosis by preventing or reversing chromatin condensation when cells encounter 
various stresses, such as microtubule inhibition 77.  The first protein to be identified as a 
component of this checkpoint pathway was the ubiquitin ligase, checkpoint with FHA 
and ring finger domains (CHFR) 78.  CHFR is a potential tumor suppressor that is 
mutated or down-regulated by promoter hypermethylation in many cancers 79.  CHFR-
deficient cells exhibit increased sensitivity to microtubule inhibitors and a failure to arrest 
in prophase under conditions of spindle stress 80.  Endogenous and ectopically 
expressed CHFR is phosphorylated during mitosis, and although this event is not well 
characterized, it has been hypothesized in one study to regulate the stability of CHFR 
81–83.  
 Similar to the phenotypes observed for CHFR-deficient cells, depletion of SNM1B 
also results in hypersensitivity to the microtubule inhibitor, nocodazole.  Additionally, 
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previous studies have shown that SNM1B and its metallo-β-lactamase/βCASP family 
member, SNM1A, are both important for delaying cell cycle progression into mitosis 
when conditions are unfavorable for division 75,84.  These findings provide evidence for a 
functional role of SNM1B in the prophase checkpoint.  It is possible that SNM1B 
phosphorylation may be a significant event in the checkpoint signaling pathway, 
potentially by promoting its stability similar to CHFR.  In support of this hypothesis, the 
S481A SNM1B mutant displays increased K48 polyubiquitination in MG132-treated 
mitotic cells compared to the WT control.  It is unlikely that CHFR is the ubiquitin ligase 
responsible for the polyubiquitination of SNM1B, as CHFR is not expressed in the 
primary cell line used in this study (HCT116).  Because CHFR is down regulated in 
various cancer cell lines, future studies examining the role of SNM1B in mitotic 
progression would need to be performed in cells that are not already deficient in the 
prophase checkpoint. 
 Based on the findings that the S481A SNM1B mutant is polyubiquitinated in 
mitosis, the phosphorylation of SNM1B may be essential for maintaining SNM1B protein 
stability.  We asked whether SNM1B phosphorylation disrupts its interaction with TRF2, 
as TRF2 binding has been previously shown to prevent polyubiquitination of SNM1B 34.  
We determined that the phosphorylation event does not disrupt this well-established 
interaction, therefore it may promote stability via an alternative mechanism.  This could 
involve a stabilizing interaction with another protein or an alteration of its local chemical 
properties and protein structure.   
In this thesis, I have identified a major phosphorylation site on SNM1B, but there 
is evidence that SNM1B may acquire additional modifications.  After nocodazole 
treatment, there is often more than one band shift observed in the Western blot and 
another slow-migrating band is frequently present in the chromatin fraction of cells 
expressing WT SNM1B (Figure 2.S2 and Figure 3.1B).  Although I focused my studies 
on the major, most reproducible SNM1B modification, future efforts could address the 
possibility of other SNM1B PTMs.  These additional PTMs could be identified through 
tandem affinity purification (TAP) and mass spectrometry using a tagged SNM1B 
construct that I have previously generated.   
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Since SNM1B is expressed at low levels and is undetectable by commercially 
available antibodies, all of our findings were based on the characterization of ectopically 
expressed V5-tagged SNM1B.  Therefore, it would be beneficial to assess whether 
endogenous SNM1B is regulated in a similar manner.  This could be achieved by 
tagging SNM1B at its native locus using modern genome editing systems, such as 
CRISPR/Cas9 85.  This would ensure that the phenotypes we observe are reproducible 
when SNM1B is expressed at physiological levels. 
In conclusion, this work provides mechanistic insight into the cell cycle-specific 
functions and regulation of the SNM1B nuclease.  We demonstrate that SNM1B 
promotes the recovery of stalled replication forks and facilitates the HR-mediated repair 
of DSBs.  We also uncover how SNM1B may be regulated during these repair 
processes through the discovery of a novel protein modification.  Overall, my thesis 
research has defined novel roles for SNM1B in resolving stalled replication forks; and 
thus, provides new insights into the molecular events that prevent the accumulation of 
replication-associated DNA damage. 
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Figure 4.1 Proposed model for cell cycle-specific functions and regulation of 
SNM1B 
(A) In response to replication stress, SNM1B becomes stabilized and localizes to stalled 
forks.  At a reversed fork, SNM1B may resect the lagging strand of the regressed arm 
using its 5’ to 3’ exonuclease activity.  This recruits members of the FA/BRCA network 
to facilitate fork protection and prevent excessive DNA degradation by other nucleases.  
After fork collapse, SNM1B may initiate DNA end resection of DSBs to generate the 3’ 
overhangs required for homologous recombination. (B) During mitosis, SNM1B 
becomes phosphorylated to maintain protein stability, as a non-phosphorylatable mutant 
is polyubiquitinated.  We hypothesize that phosphorylated SNM1B may also be involved 
in centrosome maintenance or in the resolution of anaphase bridges. (C) Defects in 
these processes or mis-regulation of SNM1B stability could result in genome instability 
in the next G1-phase, where SNM1B is no longer phosphorylated under normal 
conditions.   
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